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Most cellular processes involve dynamic interactions of signaling proteins. Chemical 
inducers of protein dimerization have been used to monitor and control these interactions in 
a spatial and temporal manner. These so called “dimerizers” are cell-permeable, small 
organic molecules that bind to specific tag protein domains. The most widely used systems is 
based on rapamycin as a dimerizer, which induces a tight binding between FKBP12 and the 
so-called FRB domain of mammalian target of rapamycin (mTOR). Although elegant and 
fast, the rapamycin-based system cannot be used to study proteins involved in growth and 
metabolism due to mTOR inhibition. 
In this PhD thesis we developed of a novel heterodimerization system based on 
protein tags devoid of endogenous signaling counterparts. Extensive structure modifications 
of these dimerizers in a pharmacochemical manner afforded highly cell permeable molecules 
that can dimerize proteins intracellularly. With the control of these molecules we now are not 
only able to dimerize any protein of interest, but can also target them to any selected cellular 
compartment.  
Utilizing this ability to target proteins to specific cellular domains, we could 
demonstrate that the dimerizer induced translocation of effector proteins to the plasma 
membrane led to a subsequent activation of downstream targets. This was shown by the 
translocation of the iSH2 domain of the regulatory subunit p85 of PI3K to the plasma 
membrane and the activation of the PI3K/PKB/mTOR pathway. In contrast to receptor ligand 
induced multiple pathway activation, our system has the power of a molecular button, 
activating single signaling cascades without affecting others. The presented small molecule-
induced heterodimerization system is suitable to selectively control signaling pathways in 
time and space, without affecting endogenous signaling systems. 
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Most cellular processes involve dynamic interactions of signaling proteins and it has 
been shown that the network of protein-protein interactions ("interact-ome") is more complex 
than previously expected [1-7]. One of many examples of such interactions is the 
dimerization of cell surface receptors by an extracellular ligand which hence activates an 
intracellular signaling cascade. Actually, most signaling events proceed their signal almost 
exclusively through protein-protein interactions, starting with the extracellular ligand-receptor 
interaction, followed by the clustering of the receptor, the intracellular activation cascade, the 
proximity driven activation of gene transcription, and even the final effector steps such as 
protein secretion [8]. 
A chemical inducer of dimerization (CID), or dimerizer, is an organic molecule with 
two separate motifs each of which bind with high affinity to a specific protein domain (Figure 
2-1). In theory, any process that is physiologically controlled by protein-protein interactions 
can be targeted by such a chemically induced dimerization strategy. This can be achieved by 
fusion of the proteins of interest (POI) to the reactive protein tag which interacts with the CID. 
Upon addition to the POI, the CID links the signaling proteins, and the cellular event, 
controlled by the dimerized signaling proteins, is activated. 
 
 
Figure 2-1 A bifunctional organic molecule brings two proteins together to induce a biological effect (adapted from 
[9]) 
 
This concept has been introduced almost 20 years ago [10] and has been widely 
adapted to various fields not only in chemical biology but also across biological research in 
general. In the following section, various heterodimerization techniques that have been 
introduced to date, their applicability but also their limits, are summarized. 
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2.1 FK506 and Rapamycin-based Systems 
2.1.1 Homodimerization with FK506 Derivatives 
The concept of chemically induced dimerization was introduced for the first time in 
1993 by Schreiber and Crabtree [10]. They were inspired by nature where small molecules 
are able to promote protein contacts. One of these molecules is the immunosuppressant 
FK506 (Figure 2-2) which simultaneously binds the FK506 binding protein 12 (FKBP12), 
which is an abundantly expressed peptidyl-prolyl cis-trans isomerase, and the signaling 
phosphatase calcineurin. Upon binding of FKBP12 to calcineurin, its phosphatase activity is 
blocked and thus its signaling inhibited [11]. 
 
 
Figure 2-2 The immunosuppressant FK506 and its derivate FK1012 
 
In their initial paper [10] Schreiber and Crabtree only used the FKBP12 binding 
capacity of FK506. By combining two FK506 molecules they obtained FK1012, a molecule 
capable of binding two FKBP12 proteins simultaneously but no longer able to bind 
calcineurin. As a proof of principle for their approach they created a T-cell receptor zeta 
chain fused to three intracellular copies of FKBP12. Upon addition of FK1012 to cells that 
express the T-cell receptor FKBP12 fusion protein a clustering of the protein and the 
associated activation of downstream cellular effects could be observed. With this approach it 
was shown that oligomerization is solely sufficient for activation of many different cellular 
processes in the absence of other influences such as extracellular stimuly [1, 12]. Later on, 
various other approaches were successful in activating downstream signals via 
oligomerization. These include the activation of FGF receptor [13-15], Fas [16], transcription 
[17], Akt [18], ZAP70 [19] and Src [20]. 
2.1.2 Heterodimerization with Rapamycin 
FK1012 is a so called homodimerizer with two identical binding motifs. If the binding 
motifs recognize two different proteins the CID is a so called heterodimerizer. With this 
bidirectionality, heterodimerization is often more precise than homodimerization and can be 
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used in a more context-dependent way. For example it allows the inducible translocation of a 
cytoplasmic protein to the cell membrane by fusing one of the CID binding proteins to a 
myristoylation motif and the other to the protein of interest [21]. By far the most common 
approach is the use of rapamycin (Figure 2-3). 
 
 
Figure 2-3 Rapamycin and the Rapalog iRap 
 
Rapamycin is a naturally occurring immunosuppressant structurally closely related to 
FK506 that similarly binds FKBP12 with high affinity [22-24]. The rapamycin-FKBP12 
complex acquires a high affinity binding site for the FKBP12 rapamycin binding protein (FRB) 
domain of mammalian target of rapamycin (mTOR). Rapamycin is highly cell permeable and 
due to its directed reaction mechanism the formation of heterodimers is very fast [23]. 
This observation of a directed heterodimerization induced by rapamycin was 
translated to an artificial system where, similar to the described process above, particular 
proteins of interest were fused to the FKBP12 protein and the FRB domain. Rapamycin 
linked the reactive domains and thus the POIs. There are numerous examples where 
rapamycin was used successfully as an intracellular heterodimerizer and only a few are 
mentioned here. Utilizing the capability of dimerizing POIs, rapamycin has been used to 
investigate pre-RNA splicing [25], protein complementation [26, 27], translation initiation [28], 
glycosylation [29], induced degradation by the proteasome [30], secretion [31], transcriptional 
activation [32, 33], and in drug discovery [33]. Even though the rapamycin-based 
heterodimerization system proved to be a versatile tool for investigating many different 
aspects of biology, one major drawback remained: Rapamycin not only links the artificially 
introduced FKBP12 and FRB fusion proteins but also the endogenous FKBP12 and mTOR, 
hence inhibiting the mammalian target of rapamycin complex 1 (mTORC1). This unwanted 
side effect leads to a stop in cell growth and metabolism [34]. To overcome this constraint, 
research focused on rapamycin derivatives, the so called rapalogs. 
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2.1.3 Rapalogs 
The solution to overcome the anti-proliferative effect of rapamycin became generally 
known as the "bumps and holes" approach [8]. For this method, rapamycin was modified with 
a bulky group (“bump”) that prevents binding with the endogenous FRB domain of mTOR. 
Then, mutations of FRB were identified that would regain the capacity of binding the rapalogs 
(“hole”). The modified CID was now only capable of binding the mutated FRB domain but not 
the endogenous protein (Figure 2-4). Several rapalogs have been described [35, 36] and one 
of them, iRap, is depicted in Figure 2-3 [37, 38]. Most rapalogs are modified at the C16 
methoxy group and this modification prevents binding with the FRB domain. FRB domains 
capable of binding rapalogs are substituted at threonine 2098 by leucin, making them very 
versatile since the binding capacity for rapamycin is not affected by this mutation. 
 
 
Figure 2-4 Rapalogs are only able to induce heterodimerization between FRB and FKBP12 fusion proteins that 
have an engineered pocket in the FRB domain. The capacity to bind FKBP12 is not impaired (adapted from[8]). 
 
Numerous publications report the use of rapalogs as a CID and claim it not to interfere with 
endogenous proteins. However, we observed that these so called rapalogs still inhibit TOR to 
a great extent (unpublished data). Reasons for this were either impurities of rapalogs by 
rapamycin, which are extremely difficult to avoid during chemical synthesis of the rapalogs, 
or undefined spatial orientation of the bulky group at the C16 position. Even if one could 
overcome these problems and hence the binding to endogenous TOR, the binding to 
FKBP12 would still remain. Both rapamycin and rapalogs bind to the conserved active site of 
all canonical FKBP members such as FKBP12. FKBPs exhibit peptidyl-prolyl cis-trans 
isomerase (PPIase) activity that is important in the slow protein folding process and are 
inhibited by rapamycin and rapalogs [22, 24, 39]. It was also shown that FKBPs are involved 
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in the modulation of Ca-channel gating and that rapamycin leads to Ca-leakage in 
endothelial cells [40]. These findings suggest that not only the inhibitory effect of rapamycin 
on TOR with its well known effects on cell growth or cell size, but also inhibition of FKBP has 
to be considered when working with rapamycin or rapalogs. 
2.2 Non-Rapamycin Systems for Intracellular Dimerization 
The rapamycin system and all variants derived from it are the oldest and by far the 
mostly used intracellular heterodimerization systems in research. An elaborate list with 
publications from this field has been compiled by Clontech [41]. However, other 
heterodimerization systems have been described as well. A summary of the systems that 
function intracellularly are summarized in the following. All of them require genetic 
manipulation of the targeted cell or organism, as with the original rapamycin or FK506 
systems. 
2.2.1 The Coumermycin System  
The first CID which was presented after the rapamycin/FK506 system was the non-
toxic natural product coumermycin [42]. Coumermycin is produced by Streptomyces and is a 
natural homodimerizer linking two amino-terminal 24K subdomains of the B subunit of 
bacterial DNA gyrase (GyrB) on each side of the molecule (Figure 2-5). 
 
 
Figure 2-5 The natural product coumermycin binds simultaneously two subdomains of GyrB 
 
In 1996, Farrar et al. first showed that the formation of homodimers of Raf-1-GyrB 
fusion proteins by coumermycin induced the activation of some downstream signaling 
proteins as the MAPK [42]. However not all downstream proteins were activated [43]. It was 
also shown with high concentrations of coumermycin that Raf-1 was not activated because of 
individually saturated binding sites preventing formation of dimers. However, Inouye et al. 
later showed that coumermycin induced dimerization of Ras was indeed able to induce Raf 
activation [44]. 
Several other signaling pathways were successfully targeted with this system. Most of 
the publications describe the Jak/Stat pathway like homo-dimerizing Jak2 [45, 46] or Tyk2 
[47] for receptor independent activation. The Stat3 homo-dimerization with coumermycin led 
to an IL-10 independent growth inhibition [48]. On the opposite, Stat5 homo-dimerization was 
not sufficient to make cells independent of IL-3, except in the presence of activated Ras [49]. 
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Coumermycin-induced homo-dimerization of numerous GyrB fusion receptors at the 
cell membrane, where the GyrB is intracellularly expressed, proved to be sufficient for their 
activation:  
- L-selectin dimerization induced a higher binding affinity to its ligand, which is an 
important step in the inflammatory response or in allergy [50].  
- Dimerization of granulocyte colony stimulating factor receptor induced cell growth and 
was proposed as a potential tool in gene therapy due to the low toxicity of 
coumermycin [51].  
- Dimerization of VEGFR allowed to study the roles of the different receptor subtypes 1 
and 2 in cells expressing endogenous VEGFR, which was previously not possible 
[52].  
- The dimerization of platelet activating factor receptor allowed the investigation of 
ligand independent receptor internalization [53].  
In summary, the coumermycin system has been proven useful and extensively 
studied. Its biggest advantage is the very low toxicity of coumermycin and that GyrB itself 
has no known function in mammalian cells. Coumermycin is a homodimerizer and there are 
many examples where homodimerization is important in cell signaling [13-20]. However, 
lacking the versatility of a heterodimerizer, its potential for biological applications is limited 
since most cell signaling events occur between different partners [54].  
2.2.2 The Biotin System 
The biotin system functions in a slightly different manner than the other systems that 
were described so far [55]. It not only needs genetic modification of the proteins of interest 
(POI) but it also requires the introduction of a third protein that acts as a catalyst. The first 
POI needs to be fused C-terminally to a 15 amino acid long sequence, called the AviTag. It is 
a substrate for the BirA biotin ligase from Escherichia coli that adds a biotin to the lysine in 
the AviTag (Figure 2-6). Because BirA does not occur naturally in eukaryotic cells it has to be 
introduced and recombinantly expressed. This is the 2nd part of the biotin system. The third 
part is the other POI that is fused to streptavidin, which binds to biotin with very high affinity. 
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Figure 2-6 BirA adds biotin to the lysine in the C-terminally expressed AviTag (adapted from [55]) 
 
In summary, upon administration of biotin to the system, BirA catalyses the 
biotinylation of biotin to the AviTag fused to one POI and then binds to the streptavidin that is 
fused to the other POI. An excess of biotin can shut off the system and no heterodimerization 
will occur [55]. 
The biotin system has been mainly used for gene expression assays. In the original 
publication by Athavankar et al. [55] the authors introduced a novel three-hybrid variant. 
They fused streptavidin to a DNA binding LexA domain and the AviTag to B42, a 
transcriptional activator. Upon addition of biotin to the system, an increase of lacZ could be 
observed. Further work was done to control gene expression with this system. The AviTag 
was fused to the transcriptional activator VP16, and streptavidin to a DNA binding module 
which lost its DNA binding capacity upon the administration of the antibiotic tetracycline [56]. 
This system allows to activate transcription upon the addition of biotin and inactivate it by 
antibiotics. The same group introduced another transcriptional regulation system [57] where 
they fused the AviTag to the DNA binding motif, and streptavidin to the KRAB 
transrepression domain. Upon addition of biotin to the transfected cells, transcription was 
turned off. 
The biotin system shows some promising results and forms highly stable 
heterodimers between the observed POI. However, the need of a third transgene in the 
system makes it more difficult to control. Further on, problems of BirA expression and 
localization in different cells and organisms have to be addressed. To circumvent this issue, 
the Peterson group has designed other CIDs for gene expression regulation in the context of 
the B42 LexA system [58, 59]. For one of those molecules they combined estrone, a ligand 
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for the estrogen receptor, with biotin (Figure 2-7). This allowed them to link streptavidin-B42 
with ER-LexA and thus to induce the transcription of LacZ. 
 
 
Figure 2-7 Biotin and estrone were successfully used as CID 
 
2.2.3 The Dexamethasone - Methotrexate System 
Another CID has been introduced by the Cornish lab [60] and showed its applicability 
in a yeast three-hybrid system. It is based on dexamethasone (DEX) and methotrexate 
(MTX). DEX is a glucocorticoid and binds with high affinity to glucocorticoid receptor (GR) 
[61]. MTX is an analog of folic acid and inhibits the folic acid pathway by binding to the 
dihydrofolate-reductase (DHFR) with picomolar affinity [62]. MTX, a potent cytotoxic 
substance, is used as a drug in various diseases including cancer and autoimmunity [63]. 
The Cornish lab made the fusion proteins GR-B42 and DHFR-LexA showing again 
that with the increase of lacZ heterodimerization was occurring. To decrease MTX toxicity, 
they exchanged MTX with the bacterial DHFR inhibitor trimethoprim but lost some reactivity 
with this exchange. The same group published also a combination of the two previously 
described systems claiming a new role of heterobifunctional molecules in systems 
engineering [64].  
An interesting variant of the DEX-MTX system was a screen for enzyme activity. By 
introducing cephalosporin as a linker between DEX and MTX (Figure 2-8) they obtained a 
CID that could indirectly sense the presence of cephalosporinase [65]. Without the enzyme 
the system worked as previously described [60], namely B42 was brought to close proximity 
to the DNA and hence lacZ was produced. However, in the presence of cephalosporinase 
the CID was cleaved and thus no translocation of B42 and production of lacZ could be 
detected. 
 
Figure 2-8 Cephalosporin is introduced between the DEX and MTX group and is cleaved by cephalosporinase 
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2.2.4 The SNAP-Tag System 
A novel method used in a heterodimerizing system was introduced by the Johnsson 
group [66, 67]. O6-benzylguanine (BG) was shown to be a potential candidate for one side of 
the double reactive heterodimerizer. BG can be a substrate for the human DNA repair protein 
O6-alkylguanine DNA alkytransferase (hAGT), which transfers irreversibly the alkyl group 
from O6-alkylguanine DNA specifically to one of its cystein residues (Figure 2-9). 
 
 
Figure 2-9 The SNAP-tag reacts covalently with O6-benzylguanine. The SNAP-tag is derived from hAGT. 
 
The substrate specificity of hAGT is relatively low and it was shown that also 
O6-benzylguanosine with substituted benzyl rings work as substrates for hAGT. To further 
increase hAGT activity and selectivity towards BG, the Johnsson group created mutants of 
hAGT and screened them, e.g. with a yeast-three hybrid system or phage display, for the 
desired properties [68-70]. The best performing resulting mutant was truncated to 182 amino 
acids, non-essential cysteins were removed, DNA binding capacity was decreased, and 
amino acids close to the active site were altered to obtain a 52-fold higher activity than wild-
type hAGT. This new improved hAGT version is called SNAP-Tag. 
The first time SNAP appeared in a heterodimerizing system was when the same 
group linked BG to MTX [71] which could be successfully used in a three hybrid system. 
Transcriptional activation was monitored in the known B42-LexA system, where DHFR was 
fused to B42 and SNAP to LexA (Figure 2-10, A). They later proved that it was also possible 
to induce homodimerization between two SNAP proteins [72] inside living cells. They could 
target SNAP-tag fusions to different cellular compartments and increase cross-linking 
efficiency when dimers were preformed with rapamycin (Figure 2-10, B).  
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The first fully covalent heterodimerization system was achieved when BG was fused 
to O2-benzylcytosin (BC)[73] which is specific for another hAGT mutant that has been 
described previously [74]. However, cross-linking was only successful when the 
heterodimers were preformed before the addition of the SNAP-CLIP heterodimerizer (Figure 
2-10, C). A double covalent system seems to be very appealing in regard of experimental 
possibilities. This covalent capture of the heterodimerization allows its detection in western- 
or immunoblots, correlating the dimerization with its cellular output. It even allows pulse 
chase experiments where unbound CIDs can be washed out of the system and administered 
later again to link only newly formed proteins.  
2.2.5 The ABA System 
Recently the Crabtree lab introduced a novel heterodimerizing system that is based 
on the plant phytohormone S-(+) abscisic acid (ABA) [75]. The ABA signaling pathway is 
important for stress response and in development. The heterodimerization achieved with 
ABA is somehow comparable to the FK506 or rapamycin system, but because there are no 
competing endogenous binding proteins ABA should not exert any toxic effects. ABA binds 
first to the pyrabactin resistance (PYR)/PYR1-like(PYL)/regulatory component of ABA 
receptor (RCAR) family receptors of intracellular receptors and the resulting complex binds 
 
Figure 2-10 SNAP has been used in different approaches for induced heterodimerization. A) BG was fused to 
MTX and used in a three hybrid system. B) BG was used as a homodimerizer and C) as a heterodimerizer 
connected to BC, a substrate specific for the CLIP tag. 
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and thus inhibits the protein phosphatase type 2Cs (PP2Cs) [76]. The binding of ABA to 
PYR/PYL/RCAR induces a conformational change that creates a binding surface to PP2C, 
forming heterodimerization [77-79]. The authors showed convincingly the applicability of this 
new CID with various examples. They were able to promote ABA induced gene transcription 
with luciferase expression assay. The yeast gal4 DNA binding domain (Gal4DBD) was fused 
to PP2C and PYL was fused to the herpes simplex virus VP16 transactivation domain 
(VP16AD). VP16AD strongly activates transcription but only in close proximity to DNA. Thus, 
only when ABA was able to induce the translocation of the VP16AD-PYL construct to the 
PP2C-Gal4DBD DNA bound construct, transcription and the formation of luciferase could be 
observed. It was also shown with microscopy that fluorescent proteins fused to the ABA 
system components could be targeted to different cellular compartments. Additionally, they 
were able to induce an activation of MAPK by the translocation of son of sevenless to the 
plasmamembrane. These results seem to be promising and future applications will show the 
applicability of this system. Especially when investigating cellular events that depend on fast 
reaction kinetics this system seems to be limited because it takes up to 12 hours until 
maximum readout of the heterodimerization is detected.  
 
 
Figure 2-11 The plant hormone ABA is able to induce heterodimerization between PP2C and PYL (adapted from 
[75]) 
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2.3 The Halo tag 
Another protein tag that has been introduced to react covalently with a specific 
chemical molecule is the Halo Tag [80]. It is based on a modified bacterial haloalkane 
dehalogenase that can form a covalent bond with a specific synthetic ligand (Figure 2-12). 
This was achieved by mutating a histidine which is normally responsible for regenerating the 
dehalogenase by hydrolysis of the covalent intermediate in the reaction. Without this 
histidine, permanent covalent linkage of the substrate to the protein was achieved. The 
authors introduced the Halo tag as a universal protein tag that could be used instead of 
fluorescent proteins (staining with Halo tag specific fluorophors) or instead of capture and 
purification tags as His and FLAG tags (Halo tag substrates bound to resin or surfaces).  
 
 
Figure 2-12 The Halo tag reacts covalently with carbon-halogen bonds in aliphatic compounds 
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2.4 Scope of Thesis 
Our group is mainly working on PI3K [81-85] and we are looking for tools allowing us 
to target members of the PI3K pathway specifically to understand their function and to 
identify their interacting partners. Numerous chemically induced heterodimerizing systems 
were published up to date. In the introduction of this thesis, only systems were presented 
that require genetic manipulation and the introduction of specific tags fused to the POI. 
We thought that chemical induced dimerization was the most promising approach to 
tamper with PI3K. With this method, potentially all proteins can be linked under the control of 
a single CID. Changing the fusion construct containing the POI and one of the reactive tags 
is much more feasible than designing a CID that brings together specifically two endogenous 
proteins. The disadvantage of such an approach is that the POI-tag-construct has to be 
introduced into the cell or whole organism, which is even more difficult. For research, these 
are problems that can be solved, since generating genetically modified animals, especially 
mice, has become a standard task. However, introducing CIDs in therapy is much more 
difficult since the patients’ cells would have to be modified genetically. 
Chemical induced dimerization can be a very powerful tool. Adapting the currently 
known systems for our research area we found no suitable tool that we could use. In our 
hands all the published systems we tested had big effects on endogenous proteins. 
Especially the rapamycin systems, and even the rapalogs claimed not to, inhibited mTOR to 
a great extent (unpublished data). This was the starting point for this PhD project and our 
goal was to develop a novel chemically induced heterodimerizing system that would not 
interfere with endogenous signaling cascades. Additionally, for better applicability, the CID 
should have a fast intracellular reactivity and have a high selectivity towards the protein tags. 
Moreover, the system should be able to be introduced into living cells and organisms and 
therefore the CID must be non-toxic, and highly cell permeable. Another important point 
would be that the linkage between the protein tags induced by the CID is stable and is not 
degraded over time. Last but not least the chemical synthesis of the CID should be feasible 
with high yield. 
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 Content 23 
Chapters 3.1 - 3.3 chronologically list all projects of this PhD thesis aiming at the 
development of a heterodimerization system to control signaling proteins in time and space. 
Each section contains a short summary of the project and is followed by a tabular synopsis of 
the molecules designed for the particular project. Subsequently, in each case the methods 
are described followed by a short discussion of the results. The most promising results of all 
projects appear in a special section (3.3.1), which includes the manuscript in preparation.  
Chapter 3.4 has only minor relation to the previous subject of chemical induced 
dimerization. However, at the beginning of my PhD thesis I invested substantial amount of 
time in targeting different PI3K isoforms with various methods. This is the reason I included 
this part in my PhD thesis. 
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3.1 SNAP-pull Project 
The first in a series of approaches to tamper with PI3K was the generation of a 
molecule capable of dragging a SNAP-tag and its attached POI to the plasma membrane 
without the need of a second reactive tag protein attached to the plasma membrane (we 
called it the SNAP-pull project). Its design differs from the classical dimerizer concept since it 
only incorporates one reactive tag. We wanted to achieve this goal by linking BG (or 
chloropyrimidine (CP), which has also been shown to react with the SNAP-tag) to a 
hydrophobic moiety that ideally would integrate in hydrophobic structures, such as the 
plasma membrane. Hydrophobic interactions alone should be sufficient to induce 
translocation of the previously cytosolic SNAP-tag to the membrane. We further planned to 
attach various proteins, such as the PI3K to the SNAP-tag that would induce a biological 
signal upon close proximity to the plasma membrane. 
However, as is described in more detail in the following sections, all structures we 
designed during the SNAP-pull project were either not reactive in cells, probably due to total 
integration in membranes, or did not translocate cytosolic proteins to any cellular 
membranes. The designed molecules were characterized according to their cellular 
distribution, intracellular reactivity, capability of translocating SNAP fusion proteins, and 
finally their capability of inducing pPKB. 
 
3.1.1 SNAP-pull Molecules 
All molecules tested during the SNAP-pull approach are depicted in Table 3-1. Our 
idea behind this chemically induced translocation method was the following: On one side, the 
molecule should incorporate a tag-reactive moiety being able to interact specifically with a 
desired protein tag. We thought the SNAP tag and its substrate BG to be ideal candidates 
due to their highly specific and stable interaction. For the other side of the molecule we 
planned a hydrophobic tail that should integrate into hydrophobic cellular structures, namely 
the plasma membrane.  
 
Hydrophilic compounds are SNAP-tag reactive are not able to pull the SNAP-tag to 
cellular membranes. Strongly lipophilic compounds on the other hand would easily interact 
with but also integrate into membranes in a manner that the reactive BG could no longer 
interact with the SNAP-tag anymore. Hence, we wanted to create intermediate molecules 
which were still SNAP-tag reactive but lipophilic enough to locate to hydrophobic cellular 
compounds.  
To follow up their intracellular distribution some molecules were designed with 
fluorophores. They were either highly hydrophobic such as the infrared fluorescent dye in 
c1271 and the hexatriene in c1408, less hydrophobic as the coumarin derivates in c1313 and 
 SNAP-pull Project 25 
c1452, or even water soluble in the case of the tetramethylrhodamine (TMR) which is part of 
the molecules c1426, c1570, c1571, and c1937. These last four compounds incorporate CP 
instead of BG as a SNAP reactive motive since it has been shown that TMR-star (a TMR 
labeled SNAP tag substrate sold by New England Biolabs) reacts specifically with the SNAP 
tag. 
 
Table 3-1 Molecules tested during the SNAP-pull approach. They all have a reactive moiety (BG or CP) and a 
hydrophobic tail. To detect the intracellular distribution, some molecules incorporate a fluorophore.  
NF:  These molecules are not fluorescent between 300 and 800 nm. 
# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] Filterset 
c1205 
BG- 
myristoyl 
 
480.6 NF NF NF 
c1271 
BG-IR- 
didecane 
 
1097.3 634 725 Cy5 
c1313 
BG-coumarin-
tridecane 
 
626.7 328 400 DAPI 
c1415 
C8-CO2Et-BG-
tridecane 
 
566.7 NF NF NF 
c1408 
BG-diphenyl 
hexatriene 
 
556.6 358 430 DAPI 
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# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] Filterset 
C 1425 
BG 
-octane-430 
 
682.8 444 484 CFP 
C 1426 
CP- 
octane-TMR 
 
882.8 554 580 TRITC 
C 1570 
CP- 
tetradecane- 
TMR 
 
967.0 554 580 TRITC 
C 1571 
CP- 
Lys palmitoyl-
TMR 
 
1080.1 554 580 TRITC 
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3.1.2 Results and Methods 
 
CELLULAR DISTRIBUTION 
Distribution of the fluorescent SNAP-pull compounds in HeLa cells was detected 
using a light microscope with the according filter sets (see Table 3-1). The coumarin 
fluorophore of C 1313 is extremely unstable and decays instantly upon exposure with light in 
the microscope. Pictures had to be taken fast without correctly adjusting the focal plane. This 
is probably why the picture shown in Figure 3-1 differs compared to the other staining 
patterns of the more stable fluorescent molecules. The picture of C 1271 in was calculated 
with a Z-stack series followed by a deconvolution, giving a more detailed look of the cellular 
compartments stained with C 1271.  
All the molecules located to a membrane-rich structure around the nucleus, probably 
to the endoplasmatic reticulum. However, localization of the molecules was never 
determined exactly. 
 
  
c1271 c1313 
 
 
c1408 c1425 
 
 
c1426 c1570 
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c1571 c1937 
Figure 3-1 Distribution of fluorescent SNAP-pull compounds in HeLa cells. HeLa cells were stained with 10µM of 
the respective compound for 30min at 37°C in comple te medium, washed and fixed with 4% PFA and visualized 
with the according filter set (Table 3-1) on an Axiovert 200 M microscope (Zeiss). Magnification is 63 fold. c1271 
was deconvoluted using Volocity program. 
 
INTRACELLULAR REACTIVITY 
HeLa cells were transfected with SNAP-GFP. Twenty-four hours later, the cells were 
first incubated with the experimental substance (10 µM) or as a reference with either TMR-
star (2 µM) or BG-430 (5 µM) for 1 hour in complete medium at 37°C. Following  this hour, the 
cells were washed twice and were then incubated with either TMR-star (2 µM) or BG-430 
(5 µM). As measure of the reactivity of the experimental substance the ratio between the 
SNAP-color picture and the GFP picture was determined. The higher the ratio, the less 
efficiently the experimental substance reacted with the SNAP-tag.  
 
 
Figure 3-2 Intracellular reactivity with SNAP-tag of selected compounds. The lower the value the better the 
reactivity of the compound. 
 
This method seemed to be useful to assess the intracellular reactivity of the 
compounds. Especially when TMR-star was used as a second step incubation (with 
molecules that are not fluorescent in the range of TMR), signal-to-noise was acceptable 
(Figure 3-2). BG-430 as a positive control and the untreated sample as a negative control 
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gave the desired results. However, for the TMR fluorescent substances (c1426, c1570, 
c1571) the second step incubation with BG-430 was not optimal as it is reflected by a high 
signal-to-noise ratio (positive control: TMR-star, negative control: untreated sample). This is 
probably due to the unfavorable fluorescent properties of BG-430. To find an alternative 
fluorescent BG-compound is difficult since it has to be fluorescent outside the GFP and TMR 
spectrum and cell permeable.  
In summary, the only compounds that were not SNAP-tag reactive inside cells are 
c1408, c1425, c1570, and c1571. Whether the molecules are not cell permeable, hide in 
intracellular hydrophobic structures, or are generally not SNAP tag reactive, could not be 
answered with this assay.  
 
TRANSLOCATION OF SNAP FUSION PROTEINS 
The idea behind the SNAP-pull project was the translocation of intracellular SNAP 
fusion proteins to the plasma membrane and in the case of PI3K the subsequent formation of 
PIP3. First experiments with the translocation of SNAP-GFP in transfected HeLa cells did not 
show any detectable redistribution of the fusion protein upon administration of any SNAP-pull 
molecule. Some of the molecules were indeed SNAP-tag reactive (see Figure 3-2) but 
somehow the drift of the hydrophobic motive within the molecule towards any cellular 
membrane due to hydrophobic interactions seemed not to be strong enough to induce a 
translocation of the proteins. To support this drift, we created SNAP fusion constructs that 
already possessed a certain tendency to translocate to cellular membranes themselves 
(Figure 3-3). This was achieved by the addition of c-terminal tails of small GTPases Rit and 
KRas4B to our SNAP constructs. They carry positive charges (from lysine) and even a 
prenylation sequence in the case of KRas. Because the full size length of the KRas and Rit 
tail solely induce translocation of attached proteins to plasma membranes, we thought that 
truncated tails ("Rit 199-219" and "Kras Delta isoprenylation" in Figure 3-3) might maintain a 
tendency to drift towards membranes but only together with a SNAP-pull molecule a 
complete translocation would occur. 
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Figure 3-3 Different SNAP constructs linked either to GFP or p110gamma fused to the C-terminus from RIT and 
KRAS. Depending on the tail, the drag to the plasma membrane differs. This was supposed to support the drift of 
the SNAP-pull molecules towards the plasma membrane leading to the translocation of the construct to the 
membrane.  
 
Transient expression of the constructs in HeLa cells as a control of the intracellular 
distribution led to the expected result (Figure 3-4). The constructs were distributed to the 
membrane when the full size tail of KRas or Rit was attached. With the truncated tails the 
membrane localization was reduced but the constructs still possessed some tendency to drift 
towards membranes compared to constructs without tails from GTPases. The constructs 
were visualized either directly with GFP or stained with the SNAP-reactive dye TMR-star. 
However, when we tried to translocate the SNAP-GFP constructs with the truncated KRas 
and Rit tail we could not detect any relocalization of the SNAP-GFP construct when 
compared to DMSO treated cells (data not shown).  
We had two explanations why our approach was not successful: Either the 
hydrophobic interaction of the SNAP-pull molecules with the membrane was still not 
sufficient even with the support of the GTPase tails, or the translocation was not prominent 
enough to be detected by eye in a light microscope. To rule out the latter, we investigated 
whether the SNAP-GFP constructs were able to activate PI3K (which would only occur upon 
translocation to the plasma membrane). 
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Figure 3-4 Distribution of SNAP-GFP and SNAP-p110g fusion proteins with a c-terminal tail of the small 
GTPases KRas and Rit. To visualize the constructs without GFP, they were stained with TMR-star, a SNAP 
reactive fluorescent compound. The experiment has been done in transfected HeLa cells. 
 
INDUCTION OF pPKB 
We transiently transfected HEK cells with SNAP p110gamma fused to the truncated 
tails of Kras and Rit (Figure 3-3) and let them grow for 24 hours. After overnight starvation 
the cells were stimulated with the compounds (5 µM for one hour). The cells were then lysed 
followed by an SDS page and a western blot against GFP. The induction of pPKB was 
measured with an antibody against S473 and normalized against total PKB. Unfortunately, 
no induction of pPKB upon addition of the SNAP-pull compounds to the transfected HEK 
cells could be observed (Figure 3-5). Interestingly, the SNAP-p110gamma-deltaRit construct 
alone induced higher pPKB levels when compared to the SNAP-p110gamma-deltaKras, 
indicating that the Rit construct still has the tendency to locate to cellular membranes. 
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Figure 3-5 SNAP-pull molecules did not induce PKB 
 
SUMMARY 
The initial idea of the SNAP-pull project seemed to be very appealing and 
theoretically possesses several advantages over a heterodimerization system for 
translocating proteins to cellular membranes. Cells only have to be transfected with one 
construct, compared to the two constructs necessary in a heterodimerization system. 
Moreover, oversaturation of the system with the chemical SNAP-pull translocator is not 
possible in contrast to a two-sided reaction system. Unfortunately these reflections stay 
purely theoretical since we were not able to induce translocation of SNAP-GFP probes to 
membranes or to induce a biological read out with SNAP-p110gamm constructs. Our findings 
are summarized in Table 3-2. Intracellular reactivity could be confirmed (Figure 2-3) but 
hydrophobic interactions between SNAP-pull compounds and the membrane were not 
sufficient. 
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Table 3-2 Summary of SNAP-pull compounds effectiveness 
Name Localization in cells Permanent 
staining? 
Intracellular 
reactivity 
SNAP GFP 
Translocation 
pPKB 
Induction 
c1205 ? ? YES NO NO 
c1271 perinuclear staining YES YES NO NO 
c1313 vesicular staining, very unstable ? YES NO NO 
c1415 ? ? YES NO NO 
c1408 perinuclear staining , bright 
spots in cytosol, unstable ? NO NO NO 
c1425 perinuclear vesicles, some 
cytosolic staining NO NO NO NO 
c1426 perinuclear staining NO YES NO NO 
c1570 perinuclear staining NO NO NO NO 
c1571 perinuclear staining NO NO NO NO 
c1937 perinuclear staining MO NO NO NO 
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3.2 SNAP-CLIP Project 
After being unsuccessful with the SNAP-pull project, we decided to establish a 
heterodimerization system based on SNAP and CLIP protein tags. CLIP tag was developed 
by the Johnsson group [74] and reacts covalently with O2-benzylcytosine (BC) residues. 
SNAP and CLIP tag have orthogonal substrate specificities and could thus be used in a 
heterodimerization system without inducing homodimerization. As will be described in detail 
in the following sections, we were able to crosslink dimers of recombinant SNAP and CLIP 
proteins that were preformed with rapamycin. Moreover, we managed to form intracellular 
SNAP and CLIP dimers in transfected cells. However, the tested dimerizers showed rather 
low cell permeability and formed only minor amounts of heterodimers in cells. Overall these 
molecules were not very promising for a heterodimerization system, and the project was 
discontinued.  
 
3.2.1 SNAP-CLIP Molecules 
With the exception of C 1559 and C 1962 all molecules presented in Table 3-3 were 
caged either on N7 or N9 position with NPE on the BG side. C 1962 and C 1984 were 
labeled with TMR to be able to detect the molecule in various assays. 
 
Table 3-3 Several SNAP-CLIP heterodimerization molecules have been produced and tested. They differ in 
length and nature of the linker, have caged or uncaged BG groups, or are fluorescent or not. 
# Name Structure Mol.wt. [g/mol] 
C 1559 BG-GLA-BC 
 
596.64 
C 1889 
N7-BG-
UPeg3-Click-
BC 
 
974.03
5 
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# Name Structure Mol.wt. [g/mol] 
C1950-
F2 
N7-NPE-BG-
GLA-BC 
 
745.8 
C1950-
F1 
N9-NPE-BG-
GLA-BC 
 
745.8 
C1952-
F2 
N7-NPE-BG-
(CH2)-BC 
 
731.8 
C1952-
F1 
N9-NPE-BG-
(CH2)-BC 
 
731.8 
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# Name Structure Mol.wt. [g/mol] 
C1962 BG-TMR-BC 
 
1'049.6 
C1984 
N7-NPE-BG-
TMR-BC 
 
1'209.7 
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3.2.2 Results and Methods 
 
RECOMBINANT HETERODIMERIZATION 
 
Figure 3-6 Heterodimers could be trapped with SNAP-CLIP dimerizers when the dimers have been preformed 
with rapamycin. 
As can be seen in Figure 3-6, recombinant SNAP FKBP and CLIP FRB proteins 
[2 µM] (kindly provided by COVALYS) were mixed in reaction buffer (100 mM HEPES, 1 mM 
DTT, 10 mM MgCl2, pH 7.2) together with rapamycin [5 µM] at 37°C fo r ten minutes. 
Following this pre-incubation with rapamycin the respective SNAP-CLIP dimerizing 
substance, previously treated with UV (365 nm, 10min), was added to the sample at a 
concentration of [5 µM] for one hour. The reaction was stopped with the addition of sample 
buffer followed by an SDS PAGE. SERVA blue R (SERVA) was used to stain the proteins. 
The gel was documented with the Odyssey (LI-COR) machine and quantified with Odyssey 
software V2.1 (LI-COR). 
Recombinant heterodimers could be formed with all the tested SNAP-CLIP 
dimerizers. The portions of dimers formed strongly depended on the molecules used and 
was the highest in the case of C 1559 (26%) and the lowest in the case of C 1984 (5%). See 
Table 3-4 for all the quantification values. 
 
CELLULAR HETERODIMERIZATION 
To test intracellular heterodimerization in the cytosol and membrane-anchored 
(Figure 3-7), HeLa cells were either co-transfected with SNAP-GFP and CLIP-GFP (top 
panel) or SNAP-GFP-CAAX and CLIP RFP (lower panel), respectively, and 24 hours later 
the according substance was administered to the cells at a concentration of 5 µM in complete 
medium, and samples were incubated for one hour at 37°C. This was followed by two 
washing steps with complete medium and a 30 min recovery at 37°C with complete medium. 
Before UV treatment, the cells were washed again with complete medium and 500 µl of 
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complete medium was added to the cells (3 cm plate). The UV (365nm) treatment was done 
on ice during 10 min. Following the procedure, 2 ml of complete medium was added to the 
plate and let react for an additional hour at 37 °C . The reaction was stopped by lysis of the 
cells in sample buffer followed by an SDS page separation and a western blot against GFP. 
The western blot was developed with HRP coupled second step antibody and conventional 
ECL. The bands were quantified with ImageJ.  
Substantial amounts of heterodimers could be detected when C 1950 F1 was used 
for the cytosolic dimerization assay (top panel). However, none of the tested molecules were 
able to induce heterodimerization between a membrane-anchored SNAP and a cytosolic 
CLIP (lower panel). 
 
 
Figure 3-7 Cellular heterodimerization 
 
Table 3-4 summarizes the properties of the SNAP-CLIP molecules in terms of their 
capacity to form heterodimers in recombinant and cellular assays. C 1950 F1 showed some 
promising results and was capable to link proteins that are expressed in the cytosol. 
However, these molecules would have to be optimized to use them in a heterodimerization 
system that is capable to tamper with signaling proteins.  
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Table 3-4 Properties of tested SNAP-CLIP molecules in terms of their capacity to form heterodimers in cellular 
and recombinant systems 
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ABSTRACT 
Signal transduction studies have unraveled a huge amount of interconnection data over the 
last decade. It has become clear that feedback loops and redundant routing of signal to 
target pathways play an important role in drug resistance, in anti-cancer and anti-
inflammative treatment. In contrast, the importance of signaling nodes in intracellular 
signaling has been very difficult to define. One reason for this is that stimulation of cells, e.g. 
by growth factor receptors activation, triggers multiple pathways at the same time. Attempts 
to stimulate isolated pathways by the expression of mutated receptors or oncogenes lead 
usually to convoluted cross-activation and feedbacks due to the prolonged timelines needed. 
The chemical activation of single signaling enzymes is therefore a very attractive strategy to 
initiate signaling at a defined starting point, and to study signal propagation throughout the 
network. Here we present the development and validation of a novel protein dimerization and 
translocation system based on protein tags that have no obvious endogenous signaling 
counterparts. The chemical dimerizers have been optimized for fast reactivity and excellent 
intra-cellular availability. The resulting system integrates chemical development and matched 
molecular biology, and offers multiple opportunities to study protein-protein interactions 
isolated or in a cellular environment. In the latter context, protein hetero-dimerization and/or 
translocation to various cellular organelles can be achieved. Sub-membrane domain 
signaling of lipid modifying enzymes like phosphoinositide kinases (PIK) and phosphatases 
(PIP) have been investigated. As an example, we demonstrate translocation of the regulatory 
subunit of PI3K to the plasma membrane hereby inducing activation of the PI3K/PKB/mTOR 
pathway. Although mainly outlined here for lipid modifying enzymes, these novel chemical 
compounds will be useful for the investigation of intra- and extracellular signaling pathways.  
  
42 Results and Methods 
INTRODUCTION 
Protein-protein interactions and their localization in cellular space determine the 
activation status of signaling cascades in physiology and disease. A striking example for 
these processes is the translocation of protein and lipid kinases to the plasma membrane 
when cells are stimulated via growth factor, immune or G protein-coupled receptors. It has 
been established recently that cytosolic or membrane localization of signaling molecules is 
crucial, but in many cases a more specific integration in signalosomes and membrane micro-
domains determines function. 
Currently available molecular tools to dissect spatial signaling include a rapamycin-
inducible FKBP12/FRB dimerization system [1, 25-27]. As the FRB domain is derived from 
target of rapamycin (TOR), rapamycin-derivatives used for this purpose interfere with a 
central hub in cellular signaling, making them unsuitable to study processes involved in the 
control of growth, immunity and metabolism control [34]. 
Recently, efforts have been concentrated on developing new strategies for combining 
the specificity afforded by a genetically encoded protein tag with the functional diversity 
enabled by synthetic chemistry that allows the incorporation of a wide range of labels [86]. A 
recently reported system for covalent labeling of fusion proteins with small molecules 
includes mutants of DNA repair protein O6-alkylguanine-DNA-alkyltransferase (SNAP-tagTM 
and CLIP-tagTM) which transfer alkyl group from their substrates, O6-benzylguanine (BG) [66] 
and O6-benzylcytosine (BC) [74], to one of its cysteine residues. Haloalkane dehalogenase 
(Halo-tagTM) has also been designed to covalently bind to synthetic chloroalkane ligands.[80] 
Covalent bond formation between these protein tags and their targeted compounds is highly 
specific, occurs rapidly under physiological conditions, and is essentially irreversible. 
Bi-valent fluorescent substrates (S-CROSS) linking SNAP- and CLIP-tagged protein 
have been recently described by Johnsson et al. [73]. However, these molecules do not 
dimerize freely diffusible proteins but only link pre-associated binding partners. One reason 
for this might be the slow reactivity of the CLIP-tag protein. Another major disadvantage of 
this method is that so far, protein cross-linking could not be achieved inside living cells, but 
only in cell lysates.  
Inspired by S-CROSS molecules described in [73], we report here the development of 
an alternative strategy to generate a library of novel hetero-bis-functional cross linkers 
containing Halo-tag and SNAP-tag substrates. This tag combination was selected based on 
the high reaction rate of the Halo- and SNAP-tags with their respective substrates [86]. The 
simplicity of the chemistry involved in our development strategy supported rapid and 
significant improvement of biological performances, and careful retrosynthetic analysis of 
protein cross-linker structure allowed rapid optimization of substrate cell permeability.  
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Here we demonstrate the development of a novel dimerization system based on 
protein tags devoid of endogenous signaling counterparts. Extensive structural modifications 
of these dimerizers in a pharmacochemical manner afforded highly cell permeable molecules 
that can dimerize proteins intracellularly. Furthermore, they may be used for targeting 
proteins to any selected cellular compartment. Thus we could demonstrate by a dimerizer-
induced translocation of the iSH2 domain of the regulatory subunit p85 of PI3K to the plasma 
membrane which led to a subsequent selective activation of downstream targets, namely the 
PI3K/PKB/mTOR pathway. The presented small molecule-induced heterodimerization 
system is thus suitable to selectively control signaling pathways in time and space, without 
affecting endogenous signaling system. 
 
RESULTS 
The Chemical Spacer Determines Fate of Dimerizer 
The nature of the chemical spacer between the SNAP- and the Halo-Tag substrate is 
crucial for cell permeability of the dimerizer. The chemical optimization of the spacer included 
integration and substitution of groups modulating water solubility, cell permeability and bulky 
or semi-rigid structures separating the two tag-reactive moieties (Figure 1a). Examples 
illustrating the development process are given below. We initiated our first study by 
modulating the length of alkyl and PEG elements. Compound c2034 was synthesized 
starting from O6-aminomethylbenzylguanine,[66] methyl succinyl chloride and Halo-PEG2-
amine [80]. A similar approach using glutaryl anhydride and 2-(2-(2-
chloroethoxy)ethoxy)ethanol yielded compound oj574 (Figure 1b). Detailed synthesis of 
compounds c2034 and oj574 can be found in Supplementary Results. Heterotypic protein 
complex formation (Halo-SNAP) was tested in recombinant assays and in cellular systems 
(e.g. Hela cells). Green fluorescent protein (GFP) was fused to the SNAP-tag protein (SNAP-
GFP) and the Halo-tag protein (Halo-GFP). As expected, excessive linker concentrations 
prevented the formation of a heterodimeric complex in vitro (Figures 1c). Similar experiments 
in transiently transfected cells demonstrated that saturation can only be reached if a very 
high amount of dimerizer is administered to the cells (Figures 1d). This suggested that the 
intracellular dimerization reaction by compounds c2034 and oj574 is diffusion limited. This 
finding is supported by the long time needed for intracellular heterodimerization compared to 
reaction speed of the reactive tags [86]. The longer linker (compound oj574) provided better 
yield of dimerization, hence we found that a certain linker length is crucial for efficient linking 
of the protein tags (Figures 1e). 
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 Figure 1 Novel heterodimerization system using Halo- and SNAP-tag proteins are capable to heterodimerize proteins 
intracellularly. (A)Halo- and SNAP-tag react covalently with great specificity to a defined chemical motive. Connecting those 
motives with a chemical spacer enables the so called dimerizer to combine the two proteins and thus bringing together the 
protein of interest fused to the tags. Chemical modification of the spacer greatly changes the properties of the dimerizer in terms 
of water solubility and cell permeability and acts as a spatial insulator between the two tag protein reactive sites. (B) Structure of 
the bis-functional Halo-SNAP reactive molecules C2034 and OJ574. They differ manly in length of the spacer region. (C) 
Recombinant SNAP-GFP and Halo-GFP fusion proteins (5 µM) were mixed with the indicated concentrations of C2034 and 
OJ574 for one hour. Optimal heterodimerization was observed when dimerizer and recombinant protein were at isomolar 
concentrations. Quantification of the concentration-dependent recombinant heterodimerization was done with three independent 
experiments (mean ± SEM). (D) Hela cells were co-transfected with SNAP-GFP and Halo-GFP. The according dimerizer was 
added to the cells in complete medium at the indicated concentration for one hour. SNAP/Halo-tag complexes were detected 
using anti-GFP primary and fluorescently labeled secondary antibodies. Quantification of the concentration-dependent 
intracellular heterodimerization was done with three independent experiments (mean ± SEM). (E) Hela cells were co-transfected 
with SNAP-GFP and Halo-GFP. The according dimerizer was added to the cells in complete medium at 5 µM for the indicated 
time. SNAP/Halo-tag complexes were detected using anti-GFP primary and fluorescently labeled secondary antibodies. 
Depicted are only the heterodimers, the full membrane can be found in the supplementary figures. Quantification of the time-
dependent intracellular heterodimerization was done with three independent experiments (mean ± SEM). 
 
Fluorine Enhances Cell Permeability 
The synthesis of oj574 analogs aimed at producing molecules with extendable 
modules maintaining a comparable length and molecular weight. As an example, oj635 was 
synthesized in a two steps sequence (see Supplementary Results for detailed synthesis), via 
monoalkylation and Jones oxidation of tetraethylene glycol, and later coupling with a glycinyl 
derivative of O6-aminomethylbenzylguanine (Figure 2a). The central glycine moiety could be 
replaced by any functionalized amino acid, thereby opening the way to a Halo-SNAP 
substrate library (Figure 2a). Excessive concentrations of oj635 did not prevent the formation 
of a heterodimeric complex in transfected HeLa cells (Figure 2b) probably due to poor cell 
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permeability and intracellular dimerization achieved by oj635 and oj574 show similar kinetics 
(Figure 2c). Within the compound oj635-derived series of molecules aimed to improve cell 
permeability, we next synthesized trifluoromethylated and pentafluorophenylated analogs 
oj582 and oj581, starting from Fmoc-trifluoromethylalanine and Fmoc-
pentafluorophenylalanine (Figure 2a). Enhancement of membrane permeation by 
introduction of fluorine atoms has been widely reported in contemporary medicinal chemistry 
[87]. To investigate the influence of fluorine atoms on cell penetration of the oj635-
derivatives, we also prepared non-fluorinated analogs (oj638 and oj637). Detailed synthesis 
of compounds oj582, oj581, oj638 and oj637 can be found in Supplementary Results. 
Fluorination indeed improved cell permeability (compare speed of dimerization for 
compounds oj638 and oj582, and oj637 and oj581, respectively, in Figure 2c. The lipophilic 
nature of the phenyl group in oj638 improved cell penetration even further. With the 
pentafluorophenyl derivative oj638 maximum dimerization could be achieved within 30 min at 
a concentration of 5 µM. Similar to recombinant heterodimerization, high concentration of 
dimerizer led to oversaturation of the cellular system and thus to less efficient cross-linking 
(Figure 2b). This finding showed that increasing cell permeability of the compound 
substantially enhances the overall speed of the heterodimerization.  
 
Figure 2 Spacer modification of Halo-SNAP dimerizers improved intracellular dimerization kinetics and capacity (A) Chemical 
structure of second generation Halo-SNAP dimerizers. To improve the intracellular dimerization capacity of the molecules, the 
linker region was modified. (B) Hela cells were co-transfected with SNAP-GFP and Halo-GFP. The according dimerizer was 
added to the cells in complete medium at the indicated concentration for one hour. SNAP/Halo-tag complexes were detected 
using anti-GFP primary and fluorescently labeled secondary antibodies. Quantification of the concentration-dependent 
intracellular heterodimerization was done with three independent experiments (mean ± SEM). (C) Hela cells were co-transfected 
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with SNAP-GFP and Halo-GFP. The according dimerizer was added to the cells in complete medium at 5 µM for the indicated 
time. SNAP/Halo-tag complexes were detected using anti-GFP primary and fluorescently labeled secondary antibodies. 
Quantification of the time-dependent intracellular heterodimerization was done with three independent experiments (mean ± 
SEM). 
 
Inspired by Lipinski's Rule of Five [88] and prediction algorithms for CaCo-2 cell 
permeability [89] results from the above series were evaluated to generate a molecule with 
even better properties in terms of cell permeability. One of the emerging strategies was to 
integrate the polyfluorophenyl substituent into the core structure of the spacer. This allowed 
reduction of the molecular weight of the dimerizer, as well as removal of an amide group. We 
also envisaged that minimizing linker flexibility would prevent steric clashes during the 
formation of the protein complex. Compound oj767 was synthesized in few steps from 
tetrafluorohydroquinone, tetraethylene glycol and 6-chloro-1-iodohexane (figure 3a). Indeed, 
the integration of fluorinated aryl moiety into the linker backbone further improved the 
properties of the dimerizer. Compared to oj581 performances, optimal dimerization could 
now be achieved with 500nM concentration of oj767 (figure 3c). To further support that cell 
permeability of the dimerizer is the limiting factor for heterodimerization speed in cells, we 
performed a parallel artificial membrane permeability assay (PAMPA) (figure 3d). As 
expected, intracellular heterodimerization speed nicely correlated with cell permeability 
values obtained by the PAMPA assay. 
 
Protein Translocation to Distinct Cellular Compartments 
The high convergence and modularity of our chemical strategy significantly improved 
the cell uptake of our “lead” compound. With the described chemical system, we targeted 
selective protein/protein cross-linking inside specific compartments of living cells. we were 
able to translocate cytosolic Halo-GFP to actin skeleton in transiently transfected NIH3T3 
cells (figure 4a). Actin was expressed as a SNAP-tag fusion protein and cross-linking with 
cytosolic Halo-GFP was induced upon addition of a 0.5 µM solution of oj767 to NIH3T3 cells. 
Translocation of the Halo-GFP fusion protein was also quantified with Pearson's correlation 
and western blot (figure 4b-d). In parallel, we were also able to induce translocation of 
fluorescent protein from cytoplasm to the plasma membrane in MDCK Cells. Cytosolic red 
fluorescent protein was expressed as Halo-tag fusion protein (Halo-RFP) and membrane 
bound green fluorescent protein was expressed as SNAP-tag fusion protein (SNAP-GFP-
CAAX). Cells were incubated with 0.5 µM solution of oj767 for 40min. We observed a 
recruitment of Halo-RFP protein to plasma membrane (figure 4e), and this translocation was 
quantified with Pearson's correlation and western blot (figure 4e-h). 
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 Figure 3 Cell permeability is crucial for fast intracellular reaction kinetics. (A) Chemical structure of third generation of Halo-
SNAP dimerizer. To improve cell permeability, the molecular weight of the dimerizer could be lowered while keeping the 
favorable properties of the fluorines. (B) A model was generated where OJ767 links the Halo- and SNAP-tag based on crystal 
structures. The model was created using the GOLD protein-ligand docking program. The SNAP-tag was moved around the 
HALO-tag to find the position with the lowest energy still capable to heterodimerize with OJ767. Energy minimization was 
performed again after covalent linking of OJ767 to D106 from the Halo-tag and to C145 from the SNAP-tag. (C) To Hela cells, 
co-transfected with SNAP-GFP and Halo-GFP, OJ767 was added in complete medium at the indicated concentrations for one 
hour. Heterodimerization was visualized by SDS-PAGE and western blot with an antibody against GFP. To compare the 
improvement in cell permeability over the three generations of dimerizers, all of them were summarized in one graph. Note the 2 
log change in optimal concentration for cellular heterodimerization from generation 1 (50µM) to generation 3 (500 nM) (mean ± 
SEM of three independent experiments). (D) Assessing the heterodimerization speed of OJ767, the compound was 
administered to SNAP-GFP and Halo-GFP co-transfected Hela cells for the indicated time at 5 µM. Heterodimerization was 
visualized by SDS-PAGE and western blot with an antibody against GFP. Shown is comparison of the best substances of each 
generation of molecules (mean ± SEM of three independent experiments). The heterodimerization speed could be improved 
dramatically by changing the nature of the spacer in Halo-SNAP dimerizers. (E) To visualize that cell permeability is the crucial 
parameter for fast intracellular reactivity, we blotted cell permeability P (obtained from the PAMPA assay, see materials and 
methods for a detailed description) against intracellular heterodimerization capacity after 15 minutes. There is a direct 
correlation between cell permeability P of the molecule and its quality as a dimerizer.  
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 Figure 4 Different cellular compartments could be targeted with OJ767 (A) NIH3T3 cells were co-transfected with SNAP-Actin 
and Halo-GFP. With the addition of OJ-767 for one hour at 0.5 µM to cells in complete medium, translocation of a cytosolic Halo 
protein to an actin-anchored SNAP protein could be observed in contrast to DMSO treated cells where no translocation was 
detected. Phalloidin-Rhodamine was administered to the fixed cells to visualize the actin cytoskeleton. (B) The translocation to 
the actin skeleton was quantified by Person’s correlation (mean ± SEM) comparing individual cells and excluding the nucleus. 
The difference was statistically significant as shown with Student's t test (p<0.01, unpaired, two-tailed). (C) Heterodimerization 
was also visualized by SDS-PAGE and western blot with an antibody against GFP. Heterodimerization was only detectable 
when OJ767 was added to the cells previous to lysis. No Heterodimerization was detected when DMSO was administered to the 
cells. (D) Quantification of the western blot of the intracellular actin heterodimerization was done with three independent 
experiments (mean ± SEM). (E) MDCK cells were co-transfected with SNAP-GFP-CAAX (from KRas4B) and Halo-RFP. 
Translocation to the plasma membrane could be observed when OJ-767 was added at a concentration 0.5 µM. DMSO did not 
lead to translocation and the Halo-RFP fusion protein stayed in the cytosol and the nucleus. (F) The translocation to the actin 
skeleton was quantified by the change of Person’s correlation over time comparing individual cells (mean ± s.e.m of three 
independent experiments). (G) Heterodimerization was also visualized by SDS-PAGE and WESTERN blot with an antibody 
against GFP. Heterodimerization was only detectable when Oj-767 was added to the cells previous to lysis. DMSO alone did not 
have this effect. (H) Quantification of the western blot of the intracellular membrane translocation was done with three 
independent experiments (mean ± SEM). 
 
 
Inducing Signal Transduction 
Protein/membrane interactions play a major role in the activation of cellular signaling 
cascades in physiology and disease. A prominent example for a signaling cascade concerted 
by relocation of signaling molecules, and changes in protein-protein and protein-lipid 
interactions, is the phosphoinositide 3-kinase (PI3K) pathway. PI3K plays a key role in the 
control of cellular responses including cellular growth, proliferation, energy metabolism, anti-
apoptotic signaling, and migration. Over-activation of PI3K has been documented to 
contribute to promotion of cancer and inflammation [83, 84, 90]. Cell surface receptor 
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stimulation or oncogene activation can trigger the activation of so-called class I PI3Ks, which 
then convert ATP and PtdIns(4,5)P2 to ADP and PtdIns(3,4,5)P3. This turnover is driven by 
PI3K catalytic subunits p110α, p110β, and p110δ, associated with one regulatory subunit 
encoded in three separate genetic loci (PIK3R1-3); or a p110γ bound to the gene product of 
PIK3R5 (p101) or PIK3R6 (p84). The three members of the class IA PI3Ks (p110α, p110β, 
and p110δ) are targeted to phosphorylated YxxM motifs on growth factor receptors and their 
substrates. The only class IB PI3K, p110γ, is activated by Gβγ subunits released from 
trimeric G proteins upon the stimulation of G protein-coupled receptors (GPCRs;[85, 91, 92]). 
That increased levels of PtdIns(3,4,5)P3 can promote cancer, inflammation and influence 
metabolic events has been illustrated in animals with non-functional phosphoinositide 
phosphatases: a loss of the 5’-inositol phosphatase SHIP1 (SH2 domain-containing inositol 
5’-phosphatase) in mice causes death by an autoimmune disorder; and the loss of the 
counter player of PI3Ks, PTEN (phosphatase and tensin homolog deleted on chromosome 
ten), leads invariably to tumor formation [93], autoimmune disorders [94] and developmental 
defects in flies and mice [95, 96]. PtdIns(3,4,5)P3 serves as a docking site for proteins with 
pleckstrin-homology (PH) domains, such as phosphoinositide-dependent kinase-1 (PDK1) 
and protein kinase B (PKB/Akt). PDK1 is required to initiate protein kinase B (PKB/Akt) 
activation by the phosphorylation of Thr308 located in the activation loop of PKB/Akt. A 
second phosphorylation of PKB/Akt on Ser473 is performed by PDK2 activities, which 
include the target of rapamycin (TOR) complex 2 (TORC2). The other TOR complex, called 
TORC1 is downstream of PKB/Akt, as PKB/Akt releases the inhibitory of action of the 
tuberosis sclerosis complex (TSC1/2) on the Rheb/TORC1 axis. TOR is an essential nutrient 
sensor, and the PI3K/PKB/TOR axis is key in the control of cell growth and cell cycle 
progression [34, 97]. Usually, translocation of PI3K is induced by stimulation of receptor 
tyrosine kinase (RTK) (e.g. the insulin receptor), its subsequent auto-phosphorylation and 
associated targeting of the regulatory subunit p85 to the membrane. 
iSH2 domain (inter–Src homology 2), a regulatory subunit of PI3K associating with 
endogenous catalytic class Ia PI3K p110, was expressed as a Halo-tag fusion protein (Halo-
iSH2). Incubation of 500nM solution of oj767 with HEK-cells transiently co-transfected with 
the Halo-iSH2 construct and a constitutively membrane tagged SNAP-GFP-CAAX probe led 
to Halo-iSH2 protein translocation to plasma membrane and activation of PI3K signaling 
cascade, leading to the formation of PtdIns(3,4,5)P3 from PtdIns(4,5)P2. Our system enabled 
a receptor-independent translocation and activation of PI3K (without RTK stimulation) and 
thus the production of PtdIns(3,4,5)P3.  
PtdIns(3,4,5)P3 production was detected by the activation status of PtdIns(3,4,5)P3 
downstream signaling proteins. Thus, PKB/Akt was phosphorylated on T308 and S473. The 
same was observed for the phosphorylation of s6K protein on T389. Phosphorylation could 
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not be detected with the sole application of DMSO, or if the SNAP tag was expressed 
cytosolic instead of membrane anchored. Our system allowed us to selectively activate the 
specific PI3K/PKB/TOR pathway, and no activation of the GRB2, SOS, Ras, MAPK could be 
detected, as shown by the missing activation of the MAPK. In contrast, activating RTKs using 
a specific ligand would lead to convoluted signals of different activated signaling cascades, 
e.g. the stimulation of a cell with insulin not only leads to the activation of the PI3K pathway 
but also to the activation of the MAPK pathway.  
When oj767 was administered to the co-transfected system, a significant increase of 
the particular pPKB at S473 levels could be observed (figure 5b). This was quantified by 
western blot in comparison with DMSO treatment and in three independent experiments. Not 
only the heterodimerization but also the localization of the iSH2 domain is important for 
signal transduction. western blot against GFP figure 5b) showed that heterodimers are 
always formed when oj767 is administered. However, only if this complex is formed at the 
plasma membrane a biological output can be generated which emphasizes the importance of 
proximity in cellular signaling cascades.  
 
Figure 5 PI3K could be activated with a membrane targeting strategy (A) The iSH2 domain of the PI3K regulatory subunit p85 
is fused to the Halo-tag and can be targeted to the membrane anchored SNAP with OJ767. This is followed by the translocation 
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of catalytic class IA PI3Ks to the plasma membrane because of its tight association with the iSH2 domain. The close proximity 
to the membrane leads to the production of PIP3 and thus the subsequent activation of the downstream signaling cascade. (B) 
Hek293 cells were co-transfected with the indicated constructs. 24 hours after transfection, the cells were starved overnight and 
afterwards stimulated with 0.5 µM of OJ767. Only when the iSH2 domain was targeted to the membrane, activation of the 
PI3K/PKB/mTOR could be observed. This was detected with western blot against the phosphorylation site T308 and S473 on 
PKB and T389 on S6K. Quantification of the western blot from three independent experiments (p<0.01,unpaired, two-tailed 
Student’s t test, ± SEM). Heterodimerization was detected with western blot against GFP. This shows nicely that not only the 
heterodimerization is crucial for signal transduction but also its localization. Cytosolic heterodimerization (lane 2) did not lead to 
a phosphorylation of signaling proteins whereas the heterodimerization at the membrane (lane 4) lead to a phosphorylation. 
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Discussion 
Here we describe a new heterodimerization system which allows controlling the 
interaction of signaling proteins intracellularly. We achieved this by the generation of a highly 
cell permeable CID which interacts covalently and highly specifically with tag proteins that 
have no endogenous counterparts. These properties have various advantages over existing 
systems, namely the rapamycin system that induces the heterodimerization of FKBP12 and 
the FRB domain of TOR. Having no endogenous counterparts, oj767 does not exhibit 
unwanted side effects like the inhibition of TOR (supplementary figure 4) as rapamycin does. 
Despite all the effort that was made to overcome this problem, like the introduction of 
chemically modified rapamycin versions that would have no effect on endogenous TOR, this 
problem has not been fully solved. In our hands, these so called rapalogues still inhibited 
TOR to a great extent (unpublished data). The reason for this were either impurities of 
rapamycin, which are extremely difficult to avoid during the synthesis of the rapalogues, or 
undefined spatial orientation of the bulky group at the C16 position of rapamycin which is 
introduced to yield the rapalog. Even if one could overcome these problems and hence the 
binding to endogenous TOR, the binding to FKBP12 would still remain. Both, rapamycin and 
rapalogues bind to the conserved active site of all canonical FKBP members such as 
FKBP12 [23]. FKBPs exhibit peptidylprolyl cis/trans isomerase (PPIase) activity that is 
important in the slow protein folding process and are thus inhibited by rapamycin [98]. It was 
also shown that FKBPs are involved in the modulation of Ca-channel gating and that 
rapamycin leads to Ca-leakage in endothelial cells [40]. These findings suggest that not only 
the inhibitory effect of rapamycin on TOR with its well known effects on cell growth or cell 
size, but also inhibition of FKBP has to be considered when working with rapamycin or 
rapalogues. 
In contrast to our newly developed system, other heterodimerizing systems capable 
of dimerizing proteins in a cellular context are all based on ligands that interact with 
endogenous proteins. Examples are estrone [60] (ligand of the estrogen receptor), 
methotrexate [65, 71] (inhibitor of the dihydrofolate reductase) or dexamethasone, a 
synthetic glucocorticoid [65].  
A further advantage of our system is the high specificity to its protein tag due to the 
covalent binding reaction. The covalent bond allows detecting the efficiency of the 
dimerization by western blot in contrast to noncovalent small molecule-protein interactions. 
Additionally the covalent reaction has the potential to enable pulse-chase experiments that 
allow tracking of proteins as a function of time. 
In summary, we describe a novel heterodimerization system based on tags with no 
endogenous counterparts that react covalently with the highly cell permeable dimerizer 
oj767. We believe that our system is especially useful in studying protein-protein interactions, 
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since it allows dissecting single steps in complex signaling pathways. The absence of 
unwanted protein inhibition, high specificity and cell permeability make oj767 a valuable tool 
in basic research. 
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3.3.1.1 Materials and Methods 
Structures of key compounds used in the study 
 
 
 
Experimental conditions 
Chemical synthesis and characterization 
Materials and reagents were of the highest commercially available grade and used without 
further purification. Reactions were monitored by thin layer chromatography using Merck 
silica gel 60 F254 plates. Compounds were visualized by UV, ceric ammonium molybdate 
(CAM), KMnO4 and ninhydrin. Flash chromatographies were performed using Merck silica 
gel 60, particle size 40 - 63 µm. 1H, 19F and 13C NMR spectra were recorded on a Bruker 
AV-400 or a DRX-600 NMR spectrometer. Chemical shifts are reported in ppm using the 
solvent residue signals as reference. All solvents used for reactions were purchased as 
anhydrous grade from Fluka. Solvents for extractions, column chromatography and TLC 
were commercial grade. Mass spectra were recorded with a VG70-250(FAB), Finnigan MAT 
MS 312 (EI) or Finnigan MAT LCQ (ESI) spectrometer. High resolution mass spectra were 
recorded with a thermo Fisher Scientific LTQ Orbitrap XL, nanoelectrospray ion source.  
 
Cell lysis and western blotting 
Cells were lysed either in “lysis buffer” or directly in “sample buffer”. The lysates were 
separated by SDS PAGE and transferred with western blot to PVDF membranes. Proteins 
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were detected with monoclonal Antibodies (mAb). mAb against GFP (Roche), phospho 
PKB/Akt (T308), phospho PKB/Akt (S473), pS6K (Cell Signaling), pMAPK (Promega) and 
MAPK (Sigma-Aldrich) were obtained commercially, antibody against total PKB was a kind 
gift from E. Hirsch. Secondary antibodies were either labeled with Alexa Fluor 680 (LI-COR) 
and detected on an Odyssey (LI-COR) infrared imaging system or were horse radish 
peroxidase conjugated (HRP) (Sigma) and were visualized by enhanced chemiluminescence 
(Millipore) and a CCD camera (Fusion Fx7, Vilber). 
 
Cloning 
The HaloTag7 coding sequence was obtained from Promega, SNAP tag (pSS26m) from 
Covalys, the iSH2 domain from Adgene and the EGFP sequence from Clonetech. These 
coding sequences were transferred by PCR (Phusion polymerase, Finnzymes) and the 
addition of appropriate restriction sites to the respective backbone. SNAP-EGFP, Halo-
EGFP, SNAP-EGFP-CAAX was expressed in pcDNA3, SNAP-Actin in pEGFP (Clonetech) 
with excised EGFP sequence, the red fluorescent tagged Halo in pTagRFP-N1 (Evrogen), 
the Halo-iSH2 domain in pEGFP-C3 (Clonetech) and for recombinant protein production His-
Halo-EGFP and His-SNAP-EGFP were cloned into pTriEx-4 (Novagen). Recombinant 
Proteins fragments were expressed as (His)6 fusion proteins and purified on Ni2+-NTA beads 
(Qiagen) according to the manufacturer’s instructions. 
 
PAMPA 
logPe was determined with the PAMPA permeation assay. For each compound, 
measurements were performed in quadruplicate at pH 7.4. Each well of a deep well plate 
was filled with 650 µl of pH-adjusted System Solution (pIon, P/N 110151). 150 µl of each well 
were transferred to an UV-plate and analyzed by UV-spectroscopy to determine the blank 
spectra. 2.5 µL of the according 2 mM compound stock solution in DMSO were added to the 
remaining System Solution in each well and mixed. To exclude precipitation, the optical 
density was measured at 650 nm, with 0.01 being the threshold value. Samples of 150 µL 
were transferred from the deep well plate to another UV-plate to determine the reference 
spectra. Further 200 µL were transferred to each well of the donor plate of the PAMPA 
sandwich. The filter membranes at the bottom of the acceptor plate were impregnated with 5 
µL of GIT-0 Lipid Solution (pIon, P/N 110669) and 200 µL of Acceptor Sink Buffer (pIon, P/N 
110139) were filled into each acceptor well. To start the experiment, the sandwich was 
assembled, then placed in the GutBoxTM and stirred for 30 minutes. To finish the assay, the 
sandwich was disassembled and 150 µL from each donor and acceptor well were transferred 
to UV-plates. Quantification was performed by both UV-spectroscopy and LC-MS. logPe-
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values were calculated based on the LC-MS results and with the aid of the PAMPA Explorer 
Software (pIon, version 3.5). 
 
Statistical Analysis 
All statistical Analysis was performed with GraphPad Prism v5. For student’s t test (two 
sided, non-paired) at least 3 independent experiments were compared. For evaluating the 
rate constant of the different heterodimerizing substances, the data of at least three 
independent experiments was nonlinear fit to Y = A - *(1-exp(-k*t)), where t is the time, Y is 
the percentage dimerized at time t, A is the maximum amount that can be dimerized by the 
respective chemical linker and k is the rate constant. 
 
Cell culture and transfection 
HeLa, Hek, MDCK and NIH3T3 (kind gift from O. Pertz) were cultured in Dulbeccos’s 
modified Eagle medium (DMEM) with 10% heat-inactivated fetal calf serum (HIFCS), 2 mM 
L-glutamine (Gln), 1% penicillin-streptomycin solution (PEST) at 37°C and 5% CO 2. Cells 
were seeded 24 hours previous the transfection with jetPEI (Polyplus-transfection) and let 
grow for at least 24 hours before the experiment was performed. 
 
Recombinant reaction 
Recombinant Halo and SNAP proteins were mixed together with the chemical dimerizer at 
the adequate concentration in reaction buffer (100mM HEPES, 1mMDTT, 10mM MgCl2, 
pH7.2) at 37°C for 4 hours. A SDS PAGE was performe d to separate and SERVA blue R 
(SERVA) to stain the proteins. The gel was documented with the Fusion Fx7 (Vilber) and 
quantified with Odyssey software V2.1 (LI-COR). 
 
Cellular heterodimerization and biological induction 
The respective dimerizer was added to the transfected cells for the desired time and 
concentration in full medium. For the biological induction, the transfected cells were starved 
overnight in medium not containing FCS before the dimerizer was added to the system for 
the indicated time. The reaction was stopped by washing the cells with ice cold PBS and 
subsequent lysis. 
 
 
 
Fluorescence Microscopy 
Cells were grown on 12mm cover slips in 24-well plates (Falcon). The transfected cells were 
either stimulated with the dimerizer or DMSO for the desired time. The reaction was stopped 
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by the addition of ice cold 4% p-formaldehyde in PBS and mounted on coverslips with 
Mowiol (Plüss-Stauffer) containing 1% Propyl gallate (Sigma-Aldrich). For staining of F-actin, 
cells were permeabilized in PBS, 1% BSA, 0.1% Triton X-100 and incubated with rhodamine-
phalloidin (Molecular Probes). For life cell microscopy the transfected cells grown on 
coverslips were mounted in life-microscopy chambers (Life Imaging Services) in the closed 
confirmation with complete medium. Pictures were taken every 30 seconds. Images were 
acquired on an Axiovert 200 M microscope (Zeiss) fitted with a Plan-Achromat 63x/1.4 oil 
objective and an Orca ER II camera (Hamamatsu) with OpenLab software (Perkin Elmer). 
The movie was made with Volocity V5.5 (Perkin Elmer) and also the calculation of the 
Pearson’s correlation with the appropriate background subtraction for every frame. 
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Supplementary methods for chemical synthesis and characterization of compounds 
 
General procedure 1 (GP1) for peptide coupling with PYBOP. PYBOP (0.2 mmol) is added to 
a solution of carboxylic acid derivative (0.2 mmol) in DMF (2 ml) at rt. The solution is stirred 
at rt for 2h. Then, amine substrate (0.2 mmol) and DIPEA (0. 2 mmol) are added and the 
solution is stirred at rt overnight. Then the crude mixture is poured onto water (70mL) and 
aqueous phase is extracted with AcOEt (2*50mL). The organic layer is washed with water 
(20mL), dried over sodium sulfate and evaporated under reduced pressure. Flash 
chromatography (FC) gives the desired compound. 
 
Synthesis of C2034. 
 
 
 
Reaction conditions: a) Methyl succinyl chloride, DIPEA, DMF, 65°C, 16h; b) 2 M NaOH, THF, rt, 1h; c) (1.) PYBOP, DMF, rt, 
3h, (2.) 2-(2-(6-chlorohexyloxy)ethoxy)ethanamine hydrochloride, DIPEA, rt, 16h. 
 
Scheme S1. Synthetic route to C2034. 
 
 
Preparation of methyl 4-(4-((2-amino-7H-purin-6-yloxy)methyl)benzylamino)-4-oxobutanoate 
(2) 
O6-aminomethylbenzylguanine (1) was prepared according to the literature.1 According to GP1, 
starting from PYBOP (481 mg, 0.92 mmol), mono-methyl succinate (122 mg, 0.92 mmol), O6-
aminomethylbenzylguanine 1 (250 mg, 0.92 mmol) and DIPEA (159 µL, 0.92 mmol). The crude 
mixture was poured into water. The resulting precipitate was collected, washed with water and dried 
under vacuum to give compound 2 (340 mg, 96%); 1H NMR (400 MHz, DMSO-d6): δ 8.38 (t, J=5.5Hz, 
1H), 7.79 (s, 1H), 7.42 (d, J=8.0Hz, 2H), 7.23 (d, J=8.0Hz, 2H), 6.55 (s, 2H), 5.43 (s, 2H), 4.23 (d, J = 
5.8Hz, 2H), 3.54 (s, 3H), 2.50 (t, J = 6.9Hz, 2H), 2.40 (t, J = 6.9Hz, 2H); 13C NMR (100.6 MHz, DMSO-
d6): δ 172.8, 170.6, 159.3, 155.4, 139.5, 138.9, 134.8, 128.5, 127.1, 66.9, 51.3, 41.8, 29.7, 28.7; MS 
(FAB, NBA): m/z (%): 385 ([M+H]+, 100), 234 (26), 202 (16), 152 (43); HRMS C18H21N6O6 [M+H]+ 
calcd: 385.1619, found: 385.1614 
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Preparation of 4-(4-((2-amino-7H-purin-6-yloxy)methyl)benzylamino)-4-oxobutanoic acid (3) 
A solution of compound 2 (410 mg, 1.07 mmol) in THF (12 mL) was stirred with NaOH (2 mL, 1M) for 
1 h at rt. THF was removed under reduce pressure and pH adjusted to 4.5 by slow addition of acetic 
acid. The resulting suspension was filtrated, the solid collected and dried under reduce pressure to 
yield the compound 3 which was used without further purification (300 mg, 76%); 1H NMR (400 MHz, 
DMSO-d6): δ 12.34 (bs, 1H), 8.39 (m, 1H), 7.84 (s, 1H), 7.44 (d, J = 7.8Hz, 2H), 7.27 (d, J = 7.8Hz, 
2H), 6.29 (s, 2H), 5.46 (s, 2H), 4.27 (m, 2H), 2.48-2.37 m, 4H); 13C NMR (100.6 MHz, DMSO-d6): δ 
174.0, 171.1, 159.7, 139.5, 135.2, 128.5, 127.2, 66.6, 41.9, 30.1, 29.2; MS (EI): m/z (%): 393 
([M+Na]+, 100), 371 (84), 342 (15); HRMS C17H19N6O4 [M+H]+ calcd: 371.1462, found: 371.1462 
 
 
Preparation of C-2034 
2-(2-(6-chlorohexyloxy)ethoxy)ethanamine hydrochloride was prepared according to the 
literature.2 According to GP1, starting from PYBOP (419 mg, 0.81 mmol), compound 3 (300 
mg, 0.81 mmmol), 2-(2-(6-chlorohexyloxy)ethoxy)ethanamine hydrochloride (209 mg, 0.81 
mmmol) and DIPEA (0.279 mL, 1.62 mmol). FC (CH2CI2/MeOH, 40:1 then 20:1) gave 
compound C-2034 (210 mg, 47%). 1H NMR (400 MHz, CDCl3 + 10% CD3OD): δ 7.33 (d, J = 
8.3Hz, 2H), 7.30 (s, 1H), 7.17 (d, J = 7.8Hz, 2H), 5.35 (s, 2H), 4.30 (s, 2H), 3.62 (m, 4H), 
3.49 (m, 4H), 3.45-3.42 (m, 4H), 3.38-3.34 (m, 2H), 3.31-3.27 (m, 2H), 2.50-2.43 (m, 4H), 
1.71-1.64 (m, 2H), 1.55-1.48 (m, 2H), 1.40-1.23 (m, 4H); 13C NMR (100.6 MHz, CDCl3 + 10% 
CD3OD): δ 173.0, 172.9, 159.5, 138.5, 135.0, 128.8, 127.7, 71.3, 70.1, 69.1, 69.6, 68.1, 45.0, 
43.2, 39.2, 32.4, 31.4, 31.3, 29.2, 26.6, 25.3; MS (FAB, NBA): m/z (%): 576 ([M+H]+, 100), 
306 (54), 202 (44), 152 (94); HRMS C27H38N7O5ClNa [M+Na]+ calcd: 598.2515, found: 
598.2509. 
 
 
Synthesis of oj574. 
 
 
 
Reaction conditions: a) (1.) NaH, THF, (2.) 6-chloro-1-iodohexane, rt, 16h; b) H2, Pd/C, MeOH, rt, 2h; c) (1.) PYBOP, DMF, rt, 
3h, (2.) 6, DIPEA, rt, 16h. 
 
Scheme S2. Synthetic route to oj574. 
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Preparation of 1-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-6-chlorohexane (5)  
Compound 4 was prepared according to the literature.3 Sodium hydride (60% in mineral oil, 
914 mg, 22.8 mmol) was added portionwise to a solution of compound 4 (2 g, 11.4 mmol) in 
THF/DMF (30mL/10mL) mixture at 0 °C. After stirring  for 30 min, 6-chloro-1-iodohexane (2.6 
mL, 17.1 mmol) was added at 0 °C. The mixture was s tirred overnight at rt. The excess of 
sodium hydride was carefully quenched with saturated solution of NH4Cl (10mL) and the 
crude mixture was poured into water (200 mL) and extracted twice with AcOEt (50 mL). The 
combined organic phase were dried over Na2SO4 and concentrated under reduce pressure. 
FC (hexane/AcOEt 1:3 then 1:1) yielded compound 5 (1.5 g, 45%). 1H NMR (400 MHz, 
CDCl3) : δ 3.66-3.61 (m, 8H), 3.56-3.48 (m, 2H), 3.50 (t, J = 6.6Hz, 2H), 3.43 (t, J = 6.6Hz, 
2H), 3.36 (t, J = 5.1Hz, 2H), 1.78-1.71 (m, 2H), 1.60-1.53 (m, 2H), 1.45-1.31 (m, 4H); 13C 
NMR (100.6 MHz, CDCl3): δ 71.6, 71.1, 71.1, 71.0, 70.5, 70.5, 51.1, 45.4, 32.9, 30.0, 27.1, 
25.8, MS (ESI-MS): m/z (%): 316 ([M+Na]+, 100); HRMS C12H24ClN3O3Na [M+Na]+ calcd: 
316.1398, found: 316.1402. 
 
 
Preparation of 2-(2-(2-(6-chlorohexyloxy)ethoxy)ethoxy)ethanamine (6) 
To a solution of compound 5 (1.8 g, 6.1 mmol) in MeOH (20 mL) was added palladium on 
charcoal (120 mg). The resulting mixture was stirred at rt for 4h under H2 atmosphere. The 
crude mixture was filtrated over celite and concentrated under reduce pressure. FC 
(DCM/MeOH + 0.5% Et3N; 10:1 then 5:1) yielded compound 6 (1.2 g, 74%). 1H NMR (400 
MHz, CDCl3) : δ 3.66-3.62 (m, 6H), 3.59-3.57 (m, 2H), 3.49-3.51 (m, 4H), 3.46 (t, J = 6.6Hz, 
2H), 2.88 (t, J = 6.6Hz, 2H), 1.93 (s, 2H), 1.79-1.75 (m, 2H), 1.60-1.57 (m, 2H), 1.46-1.34 (m, 
4H); 13C NMR (100.6 MHz, CDCl3): δ 71.6, 71.1, 71.0, 70.9, 70.8, 70.5, 70.4, 45.4, 32.9, 
29.8, 27.0, 25.8, MS (MALDI-TOF): m/z (%): 268 ([M+H]+, 100), 290 ([M+Na]+ 95) HRMS 
C12H27ClNO3 [M+H]+ calcd: 268.1674, found: 268.1675. 
 
 
Preparation of N1-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)-N5-(2-(2-(2-(6-
chlorohexyloxy)- ethoxy)ethoxy)ethyl)glutaramide OJ 574 
Compound 7 was prepared according to the literature.4 According to GP1, starting from 
PYBOP (203 mg, 0.39 mmol), compound 7 (150 mg, 0.39 mmol), compound 6 (104 mg, 0.39 
mmol) and DIPEA (68 µL, 0.39 mmol).  FC (CH2CI2/MeOH, 10:1 then 7.5:1) gave compound 
oj574 (80 mg, 32%); 1H NMR (400MHz, CD3OD) δ: 7.85 (s, 1H), 7.47 (d, J=7.8 Hz, 2H), 7.28 
(d, J=7.8 Hz, 2H), 5.52 (s, 2H), 4.36 (s, 2H), 3.58-3.49 (m, 12H), 3.42 (t, J=6.6Hz, 2H), 3.5-
3.30 (m, 3H), 2.25 (m, 4H), 1.91 (m, 2H), 1.72 (m, 2H), 1.54 (m, 2H), 1.44-1.32 (m, 4H); 13C 
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NMR (100.6 MHz, CD3OD) δ: 174.5, 174.3, 160.6, 160.3, 139.0, 135.9, 128.7, 127.7, 117.7, 
110.8, 71.1, 70.6, 70.5, 70.2, 70.1, 69.5, 67.6, 44.7, 42.9, 39.4, 35.1, 29.5, 26.7, 25.5, 22.2; 
MS (ESI-MS): m/z (%): 634 ([M+H]+, 100), 483 (20), 364 (20), 216 (30), 140 (45); HRMS 
C30H45ClN7O6 [M+H]+ calcd: 634.3114, found: 634.3125. 
 
Synthesis of oj635, oj582, oj581, oj638 and oj637. 
 
 
 
Reaction conditions: a) (1.) 8 or 9 or 10 or 11 or 12, PYBOP, DMF, rt, 3h, (2.) 1, DIPEA, rt, 16h; b) Diethylamine, DMF, rt, 3h; c) 
(1.) NaH, THF, (2.) 6-chloro-1-iodohexane, rt, 16h; d) Jones reagent, Acetone, rt, 2h; e) (1.) 25, PYBOP, DMF, rt, 3h, (2.) 18 or 
19 or 20 or 21 or 22, DIPEA, rt, 16h. 
 
Scheme S3. Synthetic route to oj635, oj582, oj581, oj638 and oj637. 
 
 
Preparation of (9H-fluoren-9-yl)methyl-2-(4-((2-amino-9H-purin-6-yloxy)methyl)benzylamino)-
2-oxoethylcarbamate (13) 
According to GP1, starting from PYBOP (289 mg, 0.55 mmol), Fmoc-Gly-OH 8 (165 mg, 0.55 
mmol), O6-aminomethylbenzylguanine (150 mg, 0.55 mmol) and DIPEA (57 µL, 0.55 mmol). 
FC (CH2CI2/MeOH, 20:1 then 10:1) gave compound 13 (246 mg, 80%). 1H NMR (400MHz, 
DMSO-d6) δ: 8.32 (m, 1H), 7.86-7.80 (m, 5H), 7.43-7.38 (m, 4H), 7.36-7.26 (m, 4H), 6,91 (m, 
1H), 6.29 (s, 2H), 6.25 (s, 2H), 5.45 (s, 2H), 4.28 (m, 2H), 3.58 (m, 1H); 13C NMR (100.6  
MHz, DMSO-d6) δ: 170.6, 160.5, 158.5, 143.4, 140.3, 140.2, 138.3, 136.0, 129.8, 129.3, 
128.2, 122.2, 120.9, 110.6, 67.4, 44.7, 42.7 MS (ESI-MS): m/z (%): 550 ([M+H]+, 100), 281 
(55); HRMS for C30H28N7O4 [M+H]+ calcd: 550.2197, found 550.2203. 
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Preparation of (9H-fluoren-9-yl)methyl-1-(4-((2-amino-9H-purin-6-yloxy)methyl)benzylamino)-
4,4,4-trifluoro-1-oxobutan-2-ylcarbamate (14) 
According to GP1, starting from PYBOP (288 mg, 0.55 mmol), (R,S)-Fmoc-2-amino-4,4,4-
trifluoro-butyric acid 9 (210 mg, 0.55 mmol), O6-aminomethylbenzylguanine (150 mg, 0.55 
mmol) and DIPEA (96 µL, 0.55 mmol). FC (CH2CI2/MeOH, 20:1 then 10:1) gave compound 
14 (226 mg, 65%). 1H NMR (400MHz, CDCl3) δ: 12.42 (m, 1H), 8.65 (t, J = 6.1Hz , 1H), 7.86 
(d, J = 7.2, 2H), 7.79 (m, 1H), 7.68 (d, J = 7.7, 2H), 7.42-7.37 (m, 4H), 7.31-7.24 (m, 4H), 
6.27 (s, 2H), 5.43 (s, 2H), 4.40-4.18 (m, 5H), 3.26 (d, J= 5.5, 1H), 2.82 (m, 1H), 2.65 (m, 1H); 
19F NMR (100.6 MHz, CDCl3) δ: -62.5; 13C NMR (100.6 MHz, CDCl3) δ: 170.5, 160.7, 160.5, 
156.6, 156.1, 144.6, 144.5, 141.6, 139.7, 129.3, 128.5, 128.1, 127.90 126.1, 126.1, 121.0, 
114.4, 67.3, 66.7, 50.1, 49.5, 47.5, 43.1; MS (ESI-MS): m/z (%): 632 ([M+H]+, 100), 281 (45); 
HRMS for C32H29F3N7O4 [M+H]+ calcd: 632.2228, found: 632.2235. 
 
 
Preparation of (S)-(9H-fluoren-9-yl)methyl- 1-(4-((2-amino-9H-purin-6- yloxy)methyl) 
benzylamino) -1-oxo-3-(perfluorophenyl)propan-2-ylcarbamate (15) 
According to GP1, starting from PYBOP (96 mg, 0.19 mmol), (R,S)-Fmoc-2-amino-4,4,4-
trifluoro-butyric acid 10 (88 mg, 0.19 mmol), O6-aminomethylbenzylguanine (50 mg, 0.19 
mmol) and DIPEA (32 µL, 0.19 mmol). FC (CH2CI2/MeOH, 20:1 then 10:1) gave compound 
15 (75 mg, 54%). 1H NMR (400MHz, DMSO-d6) δ: 12.43 (m, 1H), 8.35 (t, J=5.3 Hz, 1H), 7.86 
(m, 2H), 7.79 (s, 1H), 7.70 (m, 2H), 7.56 (t, J=6.1 Hz, 1H), 7.44-7.37 (m, 4H), 7.32-7.25 (m, 
4H), 6.30 (s, 2H), 5.44 (s, 2H), 4.29 (m, 4H), 4.28 (m, 1H), 3.65 (d, J=5.8 Hz, 2H); 19F NMR 
(100.6 MHz, DMSO-d6) δ: -68.80, -70.69, -73.92; 13C NMR (100.6 MHz, DMSO-d6) δ: 170.0, 
160.7, 160.5, 157.4, 156.1, 144.7, 141.6, 140.1, 138.7, 136.2, 129.4, 128.5, 128.2, 128.0, 
126.1, 121.0, 114.4, 67.4, 66.6, 47.5, 44.4, 42.8; MS (ESI-MS): m/z (%): 730 ([M+H]+, 100), 
280 (70), 258 (97); HRMS for C37H29F5N7O4 [M+H]+ calcd: 730.2196, found: 730.2201. 
 
 
Preparation of (S)-(9H-fluoren-9-yl)methyl-1-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl 
amino)-1-oxobutan-2-ylcarbamate (16) 
According to GP1, starting from PYBOP (231 mg, 0.44 mmol), Fmoc-Abu-OH 11 (145 mg, 
0.44 mmol), O6-aminomethylbenzylguanine (120 mg, 0.44 mmol) and DIPEA (77 µL, 0.44 
mmol). FC (CH2CI2/MeOH, 20:1 then 10:1) gave compound 16 (130 mg, 51%). 1H NMR 
(400MHz, DMSO-d6) δ: 8.43 (t, J = 5.8 Hz, 1H), 7.86 (m, 3H), 7.72 (m, 2H), 7.50-7.37 (m, 
4H), 7.38-7.25 (m, 4H), 6.28 (s, 2H), 5.45 (s, 2H), 4.30-4.15 (m, 5H), 3.94 (m, 1H), 3.17 (d, J 
= 3.0 Hz, 1H), 1.69 (m, 1H), 1.58 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR (100.6 MHz, 
DMSO-d6) δ: 173.2, 172.7, 160.5, 156.9, 144.8, 144.7, 143.4, 141.6, 140.3, 140.2, 138.3, 
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136.1, 129.8, 129.4, 129.3, 128.5, 128.2, 128.1, 128.0, 127.9, 126.2, 122.2, 120.9, 120.8, 
110.6, 67.4, 66.4, 57.0, 49.5, 47.5, 26.2, 11.4; MS (ESI-MS): m/z (%): 578 ([M+H]+, 100), 281 
(55); HRMS for C32H32N7O4 [M+H]+ calcd: 578.2510, found: 578.2520. 
 
 
Preparation of (S)-(9H-fluoren-9-yl)methyl-1-(4-((2-amino-9H-purin-6-
yloxy)methyl)benzylamino) -1-oxo-3-phenylpropan-2-ylcarbamate (17) 
According to GP1, starting from PYBOP (96 mg, 0.19 mmol), Fmoc-Phe-OH 12 (72 mg, 0.19 
mmol), O6-aminomethylbenzylguanine (50 mg, 0.19 mmol) and DIPEA (32 µL, 0.19 mmol). 
FC (CH2CI2/MeOH, 20:1 then 10:1) gave compound 17 (70 mg, 58%). 1H NMR (400MHz, 
DMSO-d6) δ: 12.42 (m, 1H), 8.55 (t, 1H, J = 5.5Hz), 7.86 (d, J = 7.5 Hz, 2H), 7.82 (s, 1H), 
7.63-7.70 (m, 3H), 7.43-7.38 (m, 4H), 7.31-7.16 (m, 8H), 6.31 (s, 2H), 5.47 (s, 2H), 4.34-4.27 
(m, 3H), 4.21-4.11 (m, 3H), 3.02 (dd, J = 4.5 Hz; 13.6 Hz, 1H), 3.02 (dd, J = 13.8 Hz; 10.6 
Hz, 1H); 13C NMR (100.6 MHz, DMSO-d6) δ: 172.2, 160.1, 159.9, 156.7, 155.8, 144.6, 141.5, 
141.5, 140.2, 139.0, 135.6, 130.1, 130.0, 128.9, 128.5, 128.1, 127.9, 127.1, 126.2, 126.1, 
120.9, 68.1, 66.5, 57.2, 47.5, 42.8, 38.5; MS (ESI-MS): m/z (%): 640 ([M+H]+, 100), 281 (40); 
HRMS for C37H34N7O4 [M+H]+ calcd: 640.2667, found: 640.2673. 
 
 
General procedure 2 (GP2) for Fmoc deprotection with diethylamine. To a solution of Fmoc 
derivative (0.39 mmol) in DMF (2mL) is added diethylamine (200µL). The resulting mixture is 
stirred at rt for one hour. Then the crude mixture is poured onto water (70mL) and aqueous 
phase is extracted with AcOEt (2*50mL). The organic layer is washed with water (20mL), 
dried over sodium sulfate and evaporated under reduced pressure. Then, desired compound 
is purified by flash chromatography (FC) or precipitated in water. 
 
 
Preparation of 2-amino-N-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)acetamide (18) 
According to GP2, starting from compound 13 (212 mg, 0.39 mmol) and diethylamine (200 
µL). FC (CH2CI2/MeOH with  Et3N (1%), 10:1 then 5:1) gives the desired compound 18 (96 
mg, 77%). 1H NMR (400MHz, DMSO-d6) δ: 8.32 (m, 1H), 7.81 (s, 1H), 7.42 (d, J=7.8 Hz, 
2H), 7.26 (d, J=7.6 Hz, 2H), 6.27 (s, 2H), 5.73 (s, 2H), 4.27 (m, 2H), 3.13 (m, 2H). 13C NMR 
(100.6 MHz, DMSO-d6) δ:160.5, 140.3, 139.3, 136.1, 129.4, 128.2, 67.4, 45.6, 42.5. MS 
(ESI-MS): m/z (%): 328 ([M+H]+, 100), 177 (25); HRMS for C15H18N7O2 [M+H]+ calcd: 
328.1516, found: 328.1520. 
 
 
64 Results and Methods 
Preparation of (S)-2-amino-N-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)-4,4,4-
trifluorobutanamide (19) 
According to GP2, starting from compound 14 (226 mg, 0.36 mmol) and diethylamine (400 
µL). FC (CH2CI2/MeOH with Et3N (1%), 10:1 then 5:1) gives the desired compound 19 (60 
mg, 41%). 1H NMR (400MHz, DMSO-d6) δ: 12.39 (s, 1H), 8.58 (t, J=5.7 Hz, 1H), 7.78 (s, 1H), 
7.42 (d, J=7.6 Hz, 2H), 7.26 (d, J=8.1 Hz, 2H), 6.27 (s, 2H), 5.43 (s, 2H), 4.27 (d, J=5.8 Hz, 
2H), 3.48 (dd, J =5.0 Hz, J =7.6 Hz 1H), 2.67 (m, 1H), 2.34 (m, 1H); 19F NMR (100.6 MHz, 
DMSO-d6) δ: -61.73; 13C NMR (100.6 MHz, DMSO-d6) δ: 173.8, 160.5, 140.0, 136.2, 129.4, 
129.2, 128.2, 126.4, 67.9, 50.8, 49.5, 42.8, 38.8. MS (ESI-MS): m/z (%): 410 ([M+H]+, 100), 
259 (25), 242 (30); HRMS for C17H19F3N7O2 [M+H]+ calcd: 410.1547, found: 410.1549. 
 
Preparation of (S)-2-amino-N-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)-3-
(perfluorophenyl) propanamide (20) 
According to GP2, starting from compound 15 (71 mg, 0.1 mmol) and diethylamine (200 µL). 
FC (CH2CI2/MeOH with  Et3N (1%), 10:1 then 5:1) gives the desired compound 20 (49 mg, 
99%). 1H NMR (400MHz, DMSO-d6) δ: 12.40 (s, 1H), 8.44 (m, 1H), 7.80 (s, 1H), 7.41 (d, 
J=7.8 Hz, 2H), 7.20 (d, J=8.1 Hz, 2H), 6.26 (s, 2H), 5.42 (s, 2H), 4.23 (m, 2H), 3.42 (m, 1H), 
2.98 (dd, J=6.6 Hz, J=13.6 Hz 1H), 2.81 (dd, J=7.9 Hz, J=13.4 Hz 1H); 19F NMR (100.6 MHz, 
DMSO-d6) δ: -141.7, -157.9, -163.4; 13C NMR (100.6 MHz, DMSO-d6) δ: 173.8, 160.5, 160.5, 
139.9, 136.2, 129.3, 128.2, 113.4, 67.6, 55.1, 42.7, 29.0; MS (ESI-MS): m/z (%): 508 
([M+H]+, 100), HRMS for C22H19F5N7O2 [M+H]+ calcd: 508.1515, found: 508.1516. 
 
 
Preparation of (S)-2-amino-N-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)butanamide (21) 
According to GP2, starting from compound 16 (130 mg, 0.22 mmol) and diethylamine (400 
µL). The resulting mixture is precipitated in water (20mL), collected and dried under reduced 
vacuum to give the desired compound 21 (73 mg, 93%). 1H NMR (400MHz, CDCl3) δ: 8.36 (t, 
J=5.5 Hz, 1H,), 7.84 (s, 1H), 7.45 (m, 2H), 7.28 (m, 2H), 6.29 (s, 2H), 5.46 (s, 2H), 4.30 (m, 
2H), 3.13 (m, 1H), 1.59 (m, 1H), 1.43 (m, 1H), 0.84 (t, J = 7.7, 3H). 13C NMR (100.6 MHz, 
CDCl3) δ: 175.8, 160.5, 140.4, 136.0, 129.4, 128.1, 67.4, 56.9, 49.4, 42.5, 28.9, 11.0. MS 
(ESI-MS): m/z (%): 356 ([M+H]+, 100), 267 (25); HRMS for C17H22N7O2 [M+H]+ calcd: 
356.1829, found: 356.1841. 
 
 
Preparation of (S)-2-amino-N-(4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)-3-phenyl 
propanamide (22) 
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According to GP2, starting from compound 17 (188 mg, 0.29 mmol) and diethylamine (400 
µL). FC (CH2CI2/MeOH with Et3N (1%), 10:1 then 5:1) gives the desired compound 22 (68 
mg, 56%). 1H NMR (400MHz, DMSO-d6) δ: 8.39 (t, J = 6.2, 1H), 7.85 (s, 1H), 7.41 (d, J = 8.1, 
2H), 7.26-7.14 (m, 7H), 6.31 (s, 2H), 5.47 (s, 2H), 4.26 (m, 2H), 3.50 (dd, J=7.7Hz; 
J=13.6Hz, 1H), 2.94 (dd, J=5.7Hz; J=13.2Hz, 1H), 2.71 (dd, J=7.4 Hz, J=13.0 Hz, 1H); 13C 
NMR (100.6 MHz, DMSO-d6) δ: 174.8, 160.5, 140.1, 139.3, 136.0, 130.2, 129.4, 129.00, 
128.1, 127.0, 67.4, 57.1, 49.5, 42.6, 41.8. MS (ESI-MS): m/z (%): 418 ([M+H]+, 100), 267 
(20), 209 (25); HRMS for C22H24N7O2 [M+H]+ calcd: 418.1986, found: 418.1992. 
 
 
Preparation of 18-chloro-3,6,9,12-tetraoxaoctadecan-1-ol (24) 
Sodium hydride (60% in mineral oil, 1.23 g, 30 mmol) was added portionwise to a solution of 
tetraethyleneglycol 23 (5 g, 25.7 mmol) in THF (250mL) at 0 °C. After stirring for 30 min, 6-
chloro-1-iodohexane (4.3 mL, 28 mmol) was added at 0 °C. The mixture was stirred 
overnight at rt. The excess of sodium hydride was carefully quenched with a saturated 
solution of NH4Cl (10 mL) and the crude mixture was poured into water (200 mL) and 
extracted twice with AcOEt (50 mL). The combined organic phase were dried over Na2SO4 
and concentrated under reduce pressure. The crude oil was purified by flash column 
chromatography (DCM/MeOH 30:1) to yield compound 24 (2.9 g, 36%). 1H NMR (400 MHz, 
CDCl3) : δ 3.7 (s, 1H), 3.63 (s, 2H), 3.58-3.50 (m, 14 H) 3.45 (t, J = 6.8Hz, 2H), 3.38 (t, J = 
6.8Hz, 2H), 3.00 (br s, 2H), 1.73-1.66 (m, 2H), 1.56-1.49 (m, 2H), 1.41-1.26 (m, 4H); 13C 
NMR (100.6 MHz, CDCl3): δ 73.1, 70.9, 70.8, 70.8, 70.4, 70.4, 61.9, 45.4, 32.9, 29.6, 27.0, 
25.7, MS (ESI-MS): m/z (%): 335 ([M+Na]+, 100), 299 (35); HRMS C14H29ClO5Na [M+Na]+ 
calcd: 335.1596, found: 335.1594. 
 
 
Preparation of 18-chloro-3,6,9,12-tetraoxaoctadecan-1-oic acid (25) 
To an ice cooled solution of the alcohol 24 (1.5 g, 4.7 mmol) in acetone (70 mL) was added 
dropwise a solution of Jone’s reagent (7.5 mL prepared according to the procedure 
described below). The solution was then stirred at rt for 4h. The crude mixture was poured 
into water (100 mL) and extracted twice with AcOEt (2x50 mL). The combined organic phase 
were combined and washed with NaHCO3 solution. The aqueous phase was acidified to pH 
1 with HCl (1M), and was extracted with AcOEt (3x50 mL). The combined organic phase 
were dried over Na2SO4 and concentrated under reduce pressure to yield compound 25 (1.2 
g, 77%). 1H NMR (400 MHz, CDCl3) : δ 10.15 (s, 1H), 4.14 (s, 2H), 3.73-3.71 (m, 2H), 3.66-
3.60 (m, 8H) 3.57-3.55 (m, 2H), 3.49 (t, J = 6.6Hz, 2H), 3.44 (t, J = 6.6Hz, 2H), 1.77-1.70 (m, 
2H), 1.60-1.53 (m, 2H), 1.45-1.29 (m, 4H); 13C NMR (100.6 MHz, CDCl3): δ 173.8, 71.7, 71.0, 
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70.9, 70.8, 70.8, 70.8, 70.5, 69.2, 45.4, 32.9, 29.7, 27.0, 25.7, MS (ESI-MS): m/z (%): 359 
([M+Na]+, 100), 313 (20); HRMS C14H27ClO6Na [M+Na]+ calcd: 349.1388, found: 349.1383. 
Preparation of Jones reagent: Concentrated H2SO4 (230 mL) was added under cooling with 
an ice bath to CrO3 (267 g, 2.67 mol) in H2O (400 mL). The cold solution is diluted with H2O 
up to 1 L to form the 8 N Jones reagent ready for use. 
 
 
Preparation of OJ 635 
According to GP1, starting from PYBOP (148 mg, 0.28 mmol), compound 18 (93 mg, 0.28 
mmol), compound 25 (93 mg, 0.28 mmol) and DIPEA (50 µL, 0.28 mmol).  FC 
(CH2CI2/MeOH, 20:1 then 10:1) gave compound oj635 (117 mg, 64%). 1H NMR (400MHz, 
CD3OD+10%CDCl3) δ: 7.80 (s, 1H), 7.42 (d, J=7.9 Hz, 2H), 7.26 (d, J=7.9 Hz, 2H), 5.48 (s, 
2H), 4.38 (s, 2H), 4.03 (s, 2H), 3.95 (m, 2H), 3.67-3.65 (m, 2H), 3.62-3.47 (m, 11H), 3.41-
3.37 (m, 2H), 1.77-1.66 (m, 2H), 1.56-1.49 (m, 2H), 1.42-1.24 (m, 4H); 13C NMR (100.6 MHz, 
CD3OD+10%CDCl3) δ:172.5, 170.3, 160.6, 138.7, 135.9, 128.7, 127.7, 71.2, 71.0, 70.5, 70.4, 
70.2, 70.1, 67.7, 44.8, 42.9, 42.2, 32.7, 29.5, 26.8, 25.5 MS (ESI-MS): m/z (%): 636 ([M+H]+, 
100), 404 (45); HRMS for C29H43ClN7O7 [M+H]+ calcd: 636.2907, found: 636.2918. 
 
 
Preparation of OJ 582 
According to GP1, starting from PYBOP (33 mg, 0.06 mmol), compound 25 (21 mg, 0.06 
mmol), compound 19 (26 mg, 0.06 mmol) and DIPEA (12 µL, 0.06 mmol).  FC 
(CH2CI2/MeOH, 20:1 then 10:1) gave compound oj582 (32 mg, 70%). 1H NMR (400MHz, 
CD3OD) δ: 7.83 (s, 1H), 7.42 (d, J=8.1 Hz, 2H), 7.26 (d, J=8.1 Hz, 2H), 5.50 (s, 2H), 4.82 (dd, 
J=4.0 Hz, J=9.6 Hz 1H), 4.37 (d, J=15.0 Hz, 1H), 4.33 (d, J=15.0 Hz, 1H), 4.05 (d, J=15.7 
Hz, 1H), 3.99 (d, J=15.7 Hz, 1H), 3.64-3.48 (m, 12H), 3.38 (m, 2H), 2.88 (m, 1H), 2.70 (m, 
1H), 1.70 (m, 2H), 1.51 (m, 2H), 1.43-1.29 (m, 4H). 19F NMR (100.6 MHz, CD3OD) δ: -65.10. 
13C NMR (100.6 MHz, CD3OD) δ:171.9, 170.2, 160.6, 138.6, 136.0, 128.7, 127.7, 127.6, 
125.3, 71.1, 70.9, 70.5, 70.4, 70.4, 70.3, 70.2, 70.1, 67.6, 46.3, 44.7, 43.1, 35.1, 32.7, 29.5, 
26.7, 26.3 25.5. MS (ESI-MS): m/z (%): 718 ([M+H]+, 100), 258 (20); HRMS for 
C31H44ClF3N7O7 [M+H]+ calcd: 718.2937, found: 718.2939. 
 
 
Preparation of OJ 581 
According to GP1, starting from PYBOP (52 mg, 0.1 mmol), compound 25 (32 mg, 0.1 
mmol), compound 20 (50 mg, 0.1 mmol) and DIPEA (17 µL, 0.1 mmol).  FC (CH2CI2/MeOH, 
20:1 then 10:1) gave compound oj581 (40 mg, 50%). 1H NMR (400MHz, CD3OD) δ: 7.82 (s, 
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1H), 7.43 (d, J=7.8 Hz, 2H), 7.23 (d, J=7.8 Hz, 2H), 5.50 (s, 2H), 4.74 (t, J=7.1.0 Hz, 1H), 
4.34 (s, 2H), 3.97 (dd, J=15.7 Hz, J=15.7 Hz, 2H), 3.61 (s, 4H), 3.59-3.56 (m, 6H), 3.50 (m, 
4H), 3.40 (m, 2H), 3;30 (m, 1H), 3.10 (m, 1H), 1.67 (m, 2H), 1.51 (m, 2H), 1.43-1.29 (m, 4H). 
19F NMR (100.6 MHz, CD3OD) δ: -143.3, -158.6, -164.8; 13C NMR (100.6 MHz, CD3OD) δ: 
171.6, 170.5, 160.6, 160.3, 147.2, 144.8, 144.7, 139.0, 138.5, 136.1, 128.7, 127.9, 111.3, 
71.1, 71.0, 70.5, 70.5, 70.5, 70.4, 70.1, 67.6, 52.0, 44.7, 43.0, 32.7, 29.5, 26.7, 25.5, 25.4. 
MS (ESI-MS): m/z (%): 816 ([M+H]+, 100), 404 (20), 258 (35); HRMS for C36H44ClF5N7O7 
[M+H]+ calcd: 816.2905, found: 816.2922. 
 
 
Preparation of OJ 638  
According to GP1, starting from PYBOP (107 mg, 0.20 mmol), compound 25 (67 mg, 0.20 
mmol), compound 21 (73 mg, 0.20 mmol) and DIPEA (36 µL, 0.20 mmol).  FC 
(CH2CI2/MeOH, 20:1 then 10:1) gave compound oj638 (40 mg, 30%). 1H NMR (400MHz, 
CD3OD) δ: 7.83 (s, 1H), 7.45 (d, J=7.8 Hz, 2H), 7.27 d, J=7.8 Hz, 2H), 5.50 (s, 2H), 4.38 (s, 
2H), 4.49 (dd, J=5.8 Hz; J=8.1 Hz, 1H), 4.02 (s, 2H), 3.67-3.48 (m, 14H), 3.42 (m, 2H), 3.30 
(m, 1H), 1.86 (m, 1H), 1.71 (m, 3H), 1.52 (m, 2H), 1.45-1.30 (m, 4H), 0.94 (t, J=7.5, 3H); 13C 
NMR (100.6 MHz, CD3OD) δ: 172.8, 171.7, 160.7, 138.8, 136.0, 128.7, 127.7, 71.1, 71.0, 
70.5, 70.5, 70.5, 70.4, 70.1, 67.6, 54.8, 44.8, 42.8, 32.7, 29.5, 26.7, 25.7, 25.5, 9.7; MS (ESI-
MS): m/z (%): 664 ([M+H]+, 100), 620 (20); HRMS for C31H47ClN7O7 [M+H]+ calcd: 664.3220, 
found: 664.3228. 
 
 
Preparation of OJ 637 
According to GP1, starting from PYBOP (81 mg, 0.16 mmol), compound 25 (51 mg, 0.16 
mmol), compound 22 (65 mg, 0.16 mmol) and DIPEA (27 µL, 0.16 mmol). FC 
(CH2CI2/MeOH, 20:1 then 10:1) gave compound oj637 (69 mg, 59%). 1H NMR (400MHz, 
DMSO-d6) δ: 12.43 (s, 1H), 8.59 (t, J=5.4, 1H), 7.81 (s, 1H), 7.70 (d, J=8.5 Hz, 2H), 7.43 (d, 
J=8.0 Hz, 2H), 7.25-7.16 (m, 7H), 6.30 (s, 2H), 5.46 (s, 2H), 4.62 (m, 1H), 4.29 (m, 2H), 3.88 
(d, J=15.3 Hz, 1H), 3.77 (d, J=15.5 Hz, 1H), 3.59 (m, 2H), 3.52 (m, 10H), 3.36 (m, 3H), 3.17 
(d, J=4.9, 1H), 3.03 (dd, J=5.0 Hz; J=13.6 Hz, 1H), 2.90 (dd, J=9.1 Hz; J=13.6 Hz, 1H), 1.67 
(m, 2H), 1.46 (m, 2H), 1.35 (m, 2H), 1.27 (m, 2H); 13C NMR (100.6 MHz, DMSO-d6) δ: 171.5, 
169.8, 160.5, 139.8, 138.4, 136.1, 130.1, 130.1, 129.4, 128.9, 128.1, 127.2, 71.0, 71.0, 70.7 
70.6, 70.5, 70.4, 70.3, 67.3, 54.2, 49.5, 46.2, 42.8, 38.6, 32.9, 29.9, 27.0, 25.8; MS (ESI-MS): 
m/z (%): 726 ([M+H]+, 100), 428 (15); HRMS for C36H49ClN7O7 [M+H]+ calcd: 726.3377, 
found: 726.3384. 
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Synthesis of OJ 767 
 
 
 
Reaction conditions: a) PPh3, CBr4, THF, rt, ov.; b) K2CO3, tert-butyl bromoacetate, DMF, rt, 4h; c) K2CO3, compound 34, DMF, 
50°C, ov.;  d) TFA, CH 2Cl2, rt, 1h; e) (1.) PYBOP, DMF, rt, 3h, (2.) 38, DIPEA, rt, 16h. 
 
Scheme S4. Synthetic route to OJ 767. 
 
 
Preparation of 1-bromo-18-chloro-3,6,9,12-tetraoxaoctadecane (26) 
To a solution of compound 24 (1.5 g, 4.8 mmol) in THF (5 mL) at 0°C are added portionwise 
triphenylphosphine (1.45 g, 5.53 mmol) and then, carbon tetrabromide (1.83 g, 5.53 mmol). 
The resulting mixture is stirred at rt overnight. Solvent is evaporated under reduced pressure 
and the crude oil is purified by flash column chromatography. FC (cyclohexane/AcOEt 3:1) 
gave compound 26 (1.23 g, 69%). 1H NMR (400 MHz, CDCl3) : δ 3.80 (m, 2H), 3.68-3.62 (m, 
10H), 3.59-3.46 (m, 8H), 1.77 (m, 2H), 1.58 (m, 2H), 1.36-1.52 (m, 4H); 13C NMR (100.6 
MHz, CDCl3): δ 72.3, 72.1, 71.6, 71.5, 71.5, 71.5, 71.4, 71.1, 45.7, 33.7, 31.4, 30.5, 27.7, 
26.5; MS (ESI-MS): m/z (%): 399.07 ([M+Na]+, 100); HRMS C14H28BrClO4Na [M+Na]+ calcd: 
399.0752, found: 399.0746. 
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Preparation of tert-butyl 2-(2,3,5,6-tetrafluoro-4-hydroxyphenoxy)acetate (28) 
To a mixture of tetrafluorohydroquinone 27 (2 g, 11 mmol) and K2CO3 (1.52 g, 11 mmol) in 
DMF (60 mL) was added dropwise a solution of tert-butyl bromoacetate (1.62 mL, 11 mmol). 
The resulting mixture was stirred at rt for 4h. The crude mixture was poured into a saturated 
solution of NH4Cl (900 mL) and extracted twice with AcOEt (2x150 mL). The combined 
organic phase were washed with NaCl solution, dried over Na2SO4 and concentrated under 
reduce pressure.  FC (cyclohexane/AcOEt 3:1) gave compound 28 (800 mg, 25%). 1H NMR 
(400 MHz, DMSO-d6): δ 11.00 (s, 1H), 4.68 (s, 2H), 1.40 (m, 9H); 13C NMR (100.6 MHz, 
DMSO-d6): δ 167.1, 81.8, 70.3, 27.6; 19F NMR (100.6 MHz, DMSO-d6) δ: -158.6, -162.4; MS 
(ESI-MS): m/z (%): 319.05 ([M+Na]+, 100); HRMS C12H12F4O4Na [M+Na]+ calcd: 319.0564, 
found: 319.0571. 
 
 
Preparation of tert-butyl-2-(4-(18-chloro-3,6,9,12-tetraoxaoctadecyloxy)-2,3,5,6-
tetrafluorophenoxy)acetate (29) 
A mixture of compound 28 (829 mg, 2.8 mmol), K2CO3 (386 mg, 2.8 mmol) and compound 
26 (1.05 g, 2.8 mmol) in DMF (5 mL) was stirred at rt overnight. The crude mixture was 
poured into a saturated solution of NH4Cl (100 mL) and extracted twice with AcOEt (2x150 
mL). The combined organic phase were combined and washed with NaCl solution, dried over 
Na2SO4 and concentrated under reduce pressure. FC (cyclohexane/AcOEt 1:1) gave 
compound 29 (1.23 g, 74%). 1H NMR (400 MHz, CD3OD) : δ 4.72 (s, 2H), 4.30 (m, 2H), 3.81 
(m, 2H), 3.67-3.60 (m, 10H), 3.59-3.55 (m, 4H), 3.50-3.45 (m, 2H), 1.76 (m, 2H), 1.57 (m, 
2H), 1.48 (m, 9H), 1.35-1.53 (m, 4H); 13C NMR (100.6 MHz, CD3OD): δ 168.8, 83.6, 75.6, 
72.1, 71.7, 71.6, 71.5, 71.5, 71.4, 71.2, 71.2, 71.1, 45.7, 33.7, 30.5, 28.3, 27.7, 26.5; 19F 
NMR (100.6 MHz, CD3OD) δ: -161.3, -161.5; MS (ESI-MS): m/z (%): 613.21 ([M+Na]+, 100); 
HRMS C26H39F4ClO8Na [M+Na]+ calcd: 613.2162, found: 613.2167. 
 
 
Preparation of 2-(4-(18-chloro-3,6,9,12-tetraoxaoctadecyloxy)-2,3,5,6-
tetrafluorophenoxy)acetic acid (30) 
To a solution of compound 29 (1g, 1.70 mmol) in DCM (2 mL) was added TFA (2 mL). The 
mixture was stirred at rt for 2h. Then, solvent was removed under reduce pressure. FC 
(DCM/MeOH 20:1) gave compound 30 (800mg, 88%). 1H NMR (400 MHz, CD3OD) : δ; 4.80 
(s, 2H), 4.30 (m, 2H), 3.81 (m, 2H), 3.65-3.59 (m, 10H), 3.59-3.55 (m, 4H), 3.47 (m, 2H), 1.76 
(m, 2H), 1.58 (m, 2H), 1.35-1.52 (m, 4H); 13C NMR (100.6 MHz, CD3OD): δ 171.3, 75.6, 72.1, 
71.7, 71.6, 71.5, 71.4, 71.1, 70.6, 45.7, 33.7, 30.5, 27.7, 26.5; 19F NMR (100.6 MHz, CD3OD) 
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δ: -159.8, -160.0; MS (ESI-MS): m/z (%): 535.17 ([M+H]+, 100); HRMS C22H32F4ClO8 [M+H]+ 
calcd: 535.1716, found: 535.1724. 
 
 
Preparation of oj767 
According to GP1, starting from PYBOP (50 mg, 0.09 mmol), compound 30 (51 mg, 
0.09mmol), O6-aminomethylbenzylguanine 1 (26 mg, 0.09 mmol) and DIPEA (17 µL, 0.09 
mmol).  FC (CH2CI2/MeOH, 20:1 then 10:1) gave oj767 (42 mg, 56%). 1H NMR (400 MHz, 
CD3OD) : δ 7.85 (s, 1H), 7.50 (m, 2H), 7.31 (m, 2H), 5.53 (s, 2H), 4.67 (s, 2H), 4.48 (s, 2H), 
4.29 (m, 2H), 3.78 (m, 2H), 3.66-3.60 (m, 10H), 3.58 (m, 4H), 3.47 (m, 2H), 1.74 (m, 2H), 
1.54 (m, 2H), 1.31-1.48 (m, 4H); 13C NMR (100.6 MHz, CD3OD): δ 169.8, 161.6, 139.6, 
137.0, 129.7, 128.7, 75.7, 73.9, 72.1, 71.7, 71.6, 71.5, 71.1, 68.7, 45.7, 43.5, 33.8, 30.6, 
27.7, 26.5; 19F NMR (100.6 MHz, CD3OD) δ: -159.2, -159.6; MS (ESI-MS): m/z (%): 787.28 
([M+H]+, 100); HRMS C35H44F4N6ClO8 [M+H]+ calcd: 787.2840, found: 787.2825. 
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3.3.1.2 Supplementary Figures 
 
Figure S1 Recombinant heterodimerization; representative SDS gels for all the substances used in this study. 
Recombinant SNAP-GFP and Halo-GFP fusion proteins (5 µM) were mixed with the 
indicated concentrations for four hours. SDS PAGE was performed and stained with SERVA 
blue. 
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Figure S2 Intracellular concentration dependant heterodimerization; representative western blots against GFP are shown for all 
substances used in this study. 
The respective dimerizer was added to Halo-GFP and SNAP-GFP co-transfected HeLa cells 
for one hour at the indicated concentration. The reaction was stopped by washing the cells 
with ice cold PBS and subsequent lysis. Heterodimerization was visualized with a western 
blot against GFP and detected on an Odyssey scanner.  
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Figure S3 Intracellular time dependant heterodimerization; representative western blots against GFP are shown for all the 
substances used in this study.  
The respective dimerizer was added to Halo-GFP and SNAP-GFP cotransfected HeLa cells 
for one hour at 5 µM. The reaction was stopped by washing the cells with ice cold PBS and 
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subsequent lysis. Heterodimerization was visualized with a western blot against GFP and 
detected on an Odyssey scanner.  
 
 
 
Figure S4 Inhibition of S6K.  
All substances were administered at 500nM for one hour to Hek cells. OJ-783 and OJ-788 
are Halo-SNAP dimerizers not covered elsewhere in this study. After lysis of the cells 
western blot against total S6K and pS6K(T389) was performed. Quantification has been 
done with three independent experiments (mean ± SEM). DMSO and the Halo-SNAP 
dimerizers (OJ-767, -783, -788) did not inhibit S6K kinase whereas iRap and rapamycin 
inhibited S6K almost completely.  
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Figure S5 Heterodimerization capacity in different cell lines 
Heterodimerization capacity of OJ581 at 5 µM in Halo-GFP and SNAP-GFP cotransfected 
cell lines was tested. The reaction was stopped by washing the cells with ice cold PBS and 
subsequent lysis. Heterodimerization was visualized with a western blot against GFP and 
detected on an Odyssey scanner. Quantification has been done with three independent 
experiments (mean ± SEM). OJ-581 showed different profiles when administered to various 
cell lines. The best results were obtained in HeLa cells, the worst in Cos-7 cells. 
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3.3.2 Additional SNAP-Halo Molecules 
The following section presents the SNAP-Halo molecules that were designed, 
produced, and tested during the development of the novel SNAP-Halo heterodimerization 
system (chapter 3.3.1). Several reasons played a role why those molecules were not 
integrated in the manuscript. The most important reason is that the majority of these 
molecules had an insufficient cell permeability either confirmed by the PAMPA assay, the 
one-sided intracellular reactivity, or the intracellular heterodimerization capacity. Some 
molecules (e.g. OJ 768) showed low reactivity in recombinant assays. This indicated that BG 
is probably a more suitable SNAP-reactive moiety than CP in the tested heterodimerization 
molecules. 
 
3.3.2.1 SNAP-Halo Molecules 
Like most of the molecules described in section 3.3.1, the generation of the here 
presented molecules (Table 3-5) were important intermediate steps during the development 
of cell permeable heterodimerizers. They mainly differ in length (C 2033, OJ 769), have CP 
instead of BG as SNAP-reactive moiety (OJ 764, OJ 768, OJ 770) or incorporate different 
side-chains that were meant to improve cell permeability. Those side-chains mostly 
incorporate fluorine atoms (OJ 552, OJ 579, OJ 709, OJ 715) except in the case of OJ 478 
and OJ 479, where a phthalimide group (a protecting group for the amine during synthesis) 
was left on the molecule to test if it was beneficial for cell permeability. 
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Table 3-5 Depicted are SNAP-Halo heterodimerization molecules that were not presented in the manuscript 
(3.2.1). However, the molecules summarized in this table were very important for the development of the highly 
cell permeable and reactive CIDs described in the manuscript. 
# Name Structure Mol.wt. [g/mol] 
C-2033 
BG-UPEG3-
Click-PEG2-
Halo 
 
818.3 
OJ 479 
BG-Phthal-
GLU-Peg2-
Amid-Peg2-
Halo 
 
880.3 
OJ 552 
BG-
Trifluoroaceta
mide-Peg2-
Halo 
N
N
N
N
H
NH2
O
H
N
O N
O
O
F
F
F
N
O
O
O
Cl
 
731.1 
OJ 579 
BG-HFPO-
Peg3-Halo 
 
870.2 
OJ 709 
BG-(5FPhe)2-
Peg4-Halo 
 
1'053.3 
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# Name Structure Mol.wt. [g/mol] 
OJ 715 
BG-(5FPhe)3-
Peg4-Halo 
 
1'290.4 
OJ769 
BG-PEG4-
Halo 
 
579.1 
OJ764 
CP-PEG4-
Halo 
 
573.5 
OJ768 
CP-5FPhe-
PEG4-Halo 
 
810.6 
OJ783 
BG-4FPhe-
PEG5-Halo 
 
831.2 
OJ788 
BG-4FPhe-
PEG6-Halo 
 
875.3 
OJ770 
CP-4FPhe-
Peg4-Halo 
 
781.6 
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3.3.2.2 Results and Methods 
 
RECOMBINANT HETERODIMERIZATION 
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Figure 3-8 Recombinant heterodimerization was optimal if CID and proteins had an equimolar concentration 
(here all 5µM). 
As can be seen in Figure 3-8, recombinant Halo and SNAP proteins [5 µM] were 
mixed with the chemical dimerizer at the adequate concentration in reaction buffer (100 mM 
HEPES, 1 mM DTT, 10 mM MgCl2, pH 7.2) at 37°C and incubated for 4 hours. An SDS  
PAGE was performed to separate and SERVA blue R (SERVA) was used to stain the 
proteins. The gel was documented with the Fusion Fx7 (Vilber) and quantified with Odyssey 
software V2.1 (LI-COR). CIDs used for this experiment are presented in section 3.3.1 and  
3.3.2.  
Optimal heterodimerization occurred when the recombinant proteins and the CID 
were equimolar (5 µM). Limited dimerization was either a result of too low a concentration of 
the dimerizer (0.5 µM) or on the other hand an excessive concentration (50 µM) of the 
dimerizer compared to the recombinant protein, where the proteins get saturated individually 
and can thus not be linked anymore. The length of the dimerizer seemed to be important for 
optimal heterodimerization of recombinant proteins (compare the short molecule C 2034 with 
the longer molecule OJ 574), but also the nature of the linker itself influenced 
heterodimerization. Fluorine atoms showed a beneficial effect on recombinant dimerization 
as can be seen when fluorinated compounds (OJ 581 and OJ 582) are compared with their 
non-fluorinated analogs (OJ 637 and OJ 638, respectively). Why this was the case we could 
only speculate about: Through a change in hydrophobicity the fluorine atoms might enhance 
the affinity of the dimerizer to the protein tags. This might be especially the case after having 
first reacted with the Halo tag (see Figure 3-9 and the following explanation). 
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In a next experiment, recombinant Halo or SNAP proteins were mixed with the 
chemical dimerizer at concentrations of 5 µM (CID and protein) in reaction buffer (100 mM 
HEPES, 1 mM DTT, 10 mM MgCl2, pH 7.2) at 37 °C. After 1 hour incubation, the ot her 
Protein (Halo or SNAP) was added at a concentration of 5 µM, followed by an additional hour 
of incubation. An SDS PAGE was performed to separate and SERVA blue R (SERVA) was 
used to stain the proteins. The gel was documented with the Fusion Fx7 (Vilber) and 
quantified with Odyssey software V2.1 (LI-COR). The molecules tested in this experiment are 
presented in the manuscript (section 3.3.1) and in this section.  
 
 
 
Figure 3-9 Recombinant heterodimerization was impaired when the compound was first incubated with the Halo 
Protein. 
 
A striking finding was that pre-incubation of the dimerizer with the Halo-GFP protein 
made the subsequent heterodimerization reaction with the SNAP-GFP much less favorable 
compared to the inverted procedure, in some cases even hardly detectable (Figure 3-9). We 
could explain this observation using molecular modeling (with the help of Marketa Zvelebil): 
The reactive amino acid in the Halo-tag (D106) is located at the bottom of a channel inside 
the protein. This channel is sufficiently long to bury reacted dimerizer completely inside the 
protein and hence making it inaccessible for reaction with the SNAP protein. This theoretical 
model was corroborated by the results shown in Figure 3-9. Long molecules (C 2033, OJ 783 
and OJ 788) which are harder to bury inside the channel maintained a better reactivity 
towards SNAP after having reacted with the Halo protein. Generally speaking, long 
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molecules have the better heterodimerization capacity for SNAP and Halo in a recombinant 
system, no matter if they react first with the SNAP or the Halo protein. However, long 
molecules also have a higher molecular weight compared to shorter ones which usually 
makes them less cell permeable. Interesting to note is that the CP analogs of the BG 
compounds (OJ 770 of OJ 767; OJ 768 of OJ 581) showed reduced capacity in 
heterodimerization of recombinant SNAP and Halo proteins, no matter if incubated first on 
the SNAP or on the Halo side. This is the reason why we optimized our Halo SNAP 
dimerizers with BG as a SNAP reactive moiety.  
 
PAMPA ASSAY 
While developing our novel SNAP-Halo heterodimerization system we observed 
dramatic differences between the various molecules in intracellular dimerization speed. We 
were soon convinced that this finding could be explained by a difference in cell permeability. 
To support our theory we wanted to correlate intracellular heterodimerization speed of our 
molecules with their cell permeability. An often used method to measure cell permeability is 
the parallel artificial membrane permeability assay (PAMPA) that determines the diffusion 
speed of a substance through an artificial membrane. This assay was performed by Matthias 
Wittwer from the Institute for Molecular Pharmacy in the group of Prof. Beat Ernst.  
For each compound, measurements were performed in quadruplicate at pH 7.4. Each 
well of a deep well plate was filled with 650 µl of pH-adjusted System Solution (pIon, P/N 
110151). Of each well, 150 µL were transferred to a UV-plate and analyzed by UV-
spectroscopy to determine the blank spectra. A volume of 2.5 µL of the according 2 mM 
compound stock solution in DMSO was added to the remaining System Solution in each well 
and mixed. To exclude precipitation, the optical density was measured at 650 nm, with 0.01 
being the threshold value. Samples of 150 µL were transferred from the deep well plate to 
another UV-plate to determine the reference spectra. Further 200 µL were transferred to 
each well of the donor plate of the PAMPA sandwich. The filter membranes at the bottom of 
the acceptor plate were impregnated with 5 µL of GIT-0 Lipid Solution (pIon, P/N 110669) 
and 200 µL of Acceptor Sink Buffer (pIon, P/N 110139) were filled into each acceptor well. To 
start the experiment, the sandwich was assembled, then placed in the GutBoxTM and stirred 
for 30 minutes. To finish the assay, the sandwich was disassembled and 150 µL from each 
donor and acceptor well were transferred to UV-plates. Quantification was performed by both 
UV-spectroscopy and LC-MS. LogPe-values were calculated based on the LC-MS results 
and with the aid of the PAMPA Explorer Software (pIon, version 3.5). 
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Figure 3-10 Cell permeability of the different compounds was measured by the diffusion through an artificial lipid 
layer (PAMPA assay). 
Figure 3-10 shows the obtained values of the substances tested. The values obtained 
with the PAMPA assay nicely correlated with the intracellular Halo SNAP heterodimerization 
speed (see 3.2.1). CIDs with a fast diffusion rate (P) were also fast in inducing intracellular 
dimers. However, there are some exceptions, namely OJ 770 and OJ 764 that have a fast 
diffusion rate but perform badly in heterodimerization. As mentioned earlier, this is probably 
due to the bad reactivity of the CP towards the SNAP tag compared to BG.  
In summary, the PAMPA assay with its prediction about cell permeability is a useful 
tool to estimate the behavior of Halo-SNAP dimerizers in intracellular heterodimerization and 
could be used to screen for novel molecules without the need of using laborious cellular 
systems. Additionally, it supports the finding that high cell permeability is the most important 
property for fast intracellular dimerization (given that the molecules are SNAP and Halo 
reactive). 
 
INTRACELLULAR ONE-SIDED REACTIVITY 
An additional method to investigate cell permeability is to test for one-sided reactivity 
of the dimerizer with its reactive tag inside cells. Leaving out the complexity of 
heterodimerization, the one sided reactivity gives a more direct read-out about cell 
permeability of the dimerizer. HeLa cells were transfected with SNAP-GFP and 24 hours 
later the according substance was administered to the cells at a concentration of 5 µM in 
completed medium, and incubated for 1 hour at 37°C.  Because the substances were non-
fluorescent, TMR-star (TMR chloropyrimidine) was added after a wash step to cells at a 
concentration of 5 µM in completed medium and incubated for an additional hour at 37°C. 
Afterwards, the cells were lysed with sample buffer and an SDS page was performed. In-gel 
fluorescence was detected with the Typhoon (Image Quant, GE healthcare) and the signal 
was normalized to GFP signal obtained after performing an anti-GFP western blot. Due to 
 SNAP-Halo Project 85 
the nature of the competition assay, the values obtained from the in-gel fluorescence come 
from the 2nd
 
step added molecule TMR-star. This means the higher the value the less protein 
was blocked from the CID in the first step, thus reflecting the CID’s low capacity of reacting 
with the Halo protein inside cells.  
The results obtained with this method (Figure 3-11) correlate with the findings from 
the PAMPA assay (Figure 3-10). Molecules showing relatively high diffusion rates (e.g. 
OJ 581 and OJ 582) performed better in this assay than molecules with slow diffusion rates 
(e.g. C 2034). Why the value of OJ 574 was even lower than the negative control DMSO was 
not investigated. This molecule showed the slowest diffusion rate in the PAMPA assay and 
might somehow influence the uptake of the second step administered TMR-star. However, 
for an optimal investigation on one-sided intracellular reactivity of the dimerizer, this 
experiment would have to be adapted: More time-points should be measured, since a single 
reactivity determination after one hour does not answer the kinetics of the molecules. 
However this so called "competition assay" is a valuable method to test intracellular reactivity 
of non-fluorescent molecules.  
 
 
Figure 3-11 Intracellular reactivity of CIDs on the SNAP tag side. The reactivity is measured indirectly by the 
addition of TMR-star after the incubation with the dimerizer. Only unreacted SNAP tag can react with the TMR-
star, thus high TMR fluorescence can be detected in only in samples pre-incubated with CIDs that have only little 
reacted. BTP is a positive control molecule, containing  a bromine connected to BG. 
 
INTRACELLULAR HETERODIMERIZATION 
As shown in Figure 3-8 concentration of the CID strongly influences the 
heterodimerization process. Too high a concentration leads to individually saturated protein 
tags that cannot be linked anymore, and heterodimerization fails. To assess the intracellular 
heterodimerization capacity, the ideal concentration of dimerizer had to be determined first. 
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To find out if this applies also in cells we co-transfected HeLa cells with SNAP-GFP and 
Halo-GFP, and 24 hours later the according substance was administered to the cells at 
various concentrations (50 nM, 500 nM, 5 µM, and 50 µM) in completed medium, and 
incubated for 1 hour at 37°C. The reaction was stop ped by lysis of the cells in sample buffer 
followed by an SDS page and a western blot against GFP. The amount of heterodimers 
formed during the incubation hour was quantified with fluorescent 2nd step antibodies on an 
Odyssey (LI-COR) machine. The molecules tested in Figure 2-12 were presented in chapter 
3.3.1 and 3.3.2.  
After having tested different concentration of CIDs for intracellular heterodimerization 
in HeLa cells, it became clear that most of the compounds were ideally administered at a 
concentration of 5 µM. At 500 nM, however, the best performing compounds (OJ 767, OJ 
788, and OJ 783) dimerized to an even larger amount. Interesting to note is that the system 
could not be saturated with the compounds that had the lowest diffusion rate measured in the 
PAMPA assay (OJ 574 and OJ 635). This illustrates nicely that intracellular 
heterodimerization is a diffusion-driven reaction and the rate determining factor of the 
dimerization is the diffusion of the CID through the cell membrane. 
 
 
Figure 3-12 The amount needed for optimal heterodimerization depends strongly on the nature of the CID. The 
graphs show the quantification of three independent experiments ± SEM. 
 
With this information, we tested the substances presented in section 3.3.1 and 3.3.2. 
The experiments presented in the following three figures (Figure 3-13, Figure 3-14 and 
Figure 3-15) were performed in a similar fashion: HeLa cells were co-transfected with SNAP-
GFP and Halo-GFP, and 24 hours later the according substance was administered to the 
cells at a concentration of 5 µM in completed medium and incubated for the indicated time at 
37°C. The reaction was stopped by lysis of the cell s in sample buffer followed by an SDS 
page and a western blot against GFP. The amount of heterodimers formed during the 
incubation hour was quantified with fluorescent second step antibodies on an Odyssey (LI-
COR) machine. 
The experiment displayed in Figure 3-13 shows that all the molecules dimerize Halo 
and SNAP inside HeLa cells after one hour to more or less the same extent (with maybe the 
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exception of C-2033). In this preliminary experiment, we only measured a single time point 
for various molecules, which made an evaluation of their kinetic profile impossible. However, 
it gave in advance important information in a yes-or-no manner: Do the molecules dimerize 
or not. 
 
 
Figure 3-13 Intracellular heterodimerization capacity of CID after one hour incubation with the dimerizers. 
 
As we learned from the PAMPA assay, the diffusion rates among the various 
molecules differ dramatically. Hence, we expected the various CIDs to have different kinetic 
profiles of intracellular heterodimerization. For this purpose, the amount of dimers formed 
after different time points had to be measured.  
Figure 3-14 shows a typical experiment where we compared the three structurally 
related molecules OJ 581, OJ 709, and OJ 715. Once more one of the biggest advantages of 
our dual covalent heterodimerization system became evident: Due to the stable linkage of 
the dimerizers with their protein tags, the formed dimers were even visible in western blots. 
With this direct read-out we were able to optimize our dimerizers towards fast cell 
permeability. In contrast, if one had to rely on indirect read-outs such as gene expression 
assays, the impact of the dimerization speed would be less prominent since the time from the 
induction with the dimerizer to the final read-out would take hours. Small changes of 
permeability would not be detected thus making it more difficult to gradually improve the 
CIDs. 
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Figure 3-14 The rate of which heterodimers are formed inside living cells depends greatly on the nature of the 
CID.  
 
Figure 3-15 gives an overview over the kinetic intracellular heterodimerization profile 
of the various SNAP Halo dimerizers presented in section 3.3.1 and 3.3.2. As in the previous 
experiments, HeLa cells were co-transfected with SNAP-GFP and Halo-GFP and 24 hours 
later the according substance was administered to the cells at a concentration of 5 µM in 
completed medium, and incubated for the indicated time at 37°C. The reaction was stopped 
by lysis of the cells in sample buffer followed by an SDS page and a western blot against 
GFP. The amount of heterodimers formed during the incubation hour was quantified with 
fluorescent 2nd step antibodies on an Odyssey (LI-COR) machine.  
To be able to compare the molecules for their short and long time behavior, the 
molecules were once depicted on a 60 minutes time axis (left side of the panel) and on a 500 
minutes time axis (right side of the panel) (Figure 3-15). The 16 CIDs were distributed in 
groups of 4 and ordered from slow to fast heterodimerization capacity to facilitate the 
comparison among the CIDs. 
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Figure 3-15 Intracellular reaction speed of various compounds. The graphs show the quantification of three 
independent experiments ± SEM.  
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3.3.3 Caged SNAP-Halo Molecules 
It was shown by the Johnsson group in 2008 [99] that caging the position N7 of a BG 
by a nitrophenyl group prevents it from reacting with the SNAP tag. This cage is cleaved by 
illumination at 360 nm making the BG accessible for the SNAP tag again. Such a light 
induced heterodimerization has several advantages over a system not incorporating this 
feature. In contrast to non-caged CIDs, an oversaturation of the system is not possible since 
after reaction on the uncaged side of the dimerizer (in our case the Halo-side) the excess, 
non-reacted dimerizers can be washed out. This leaves behind fully saturated Halo tag 
proteins and ideally unsaturated SNAP tag proteins that can be linked instantly upon UV 
activation. Pre-loading the cells with the CID can be done over a long period of time (no 
heterodimers are formed as long as the molecule is caged) thus the cell permeability of the 
molecules is not as important as with uncaged molecules. An additional advantage of light 
induced heterodimerization is the possible control in local heterodimer formation. UV light 
can be applied to cells with high precision, irradiating only desired regions of the cell, like a 
distinct area of the cell membrane. With this method, local production of PIP3 is feasible by 
targeting PI3K only to the area where the BG has been uncaged. Inspired by this, we 
investigated the implementation of a caged BG in our dimerizing systems, namely by 
attaching a single 1-(2-nitrophenyl)-ethyl group (NPE) to position N7 and alternatively to N9. 
The following sections address several problems that occurred during the design of 
caged SNAP-Halo dimerizers. In short, caging BG at the correct position is of high 
importance, because similarly to what Banala et al. reported [99], we found more residual 
reactivity of caged BG towards SNAP when the cage was attached at position N9 compared 
to N7. Illumination at 365 nm successfully induced dimerization with some molecules. Other 
molecules showed either high background dimerization before UV-irradiation or did not form 
dimers after UV-treatment at all. Especially short Halo-SNAP dimerizers did not yield dimers 
after UV-treatment. This finding might be once again explained by the deep binding pocket of 
the Halo protein (see also Figure 3-9).  
3.3.3.1 Caged SNAP-Halo Molecules 
Table 3-6 depicts all the caged SNAP-Halo molecules produced and tested within this 
project. These were N7 and N9 caged analogs of the molecules already described in 
sections 3.3.1 and 3.3.2. Hence, we were able to draw conclusions on structure-activity 
relationships. For the following results section, the caged molecules are always compared 
with the uncaged analogs presented in section 3.3.1 and 3.3.2. 
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Table 3-6 Caged SNAP-Halo molecules. The NPE group was attached on position N7 or N9 on the BG. Only 
after uncaging of the NPE with UV light, the BG becomes SNAP tag reactive. 
# Name Structure Mol.wt. [g/mol] 
OJ 448 
or 
C-2008 
N7-NPE-BG-
UPEG3-Click-
PEG2-Halo 
 
967.5 
C-2009 
N9-NPE-BG-
UPEG3-Click-
PEG2-Halo 
 
967.5 
OJ 447 
or 
C-2058 
F2 
N7-NPE-BG-
(CH2)2-PEG2-
Halo 
 
725.2 
OJ 446 
or 
C-2058 
F1 
N9-NPE-BG-
(CH2)2-PEG2-
Halo 
 
725.2 
OJ 480 
F1 
N9-NPE-BG-
Phthal-GLU-
Peg1-Amid-
Peg2-Halo 
N
N
N
N NH2
NO2
O
N
H
O
O
ON
Cl
O
NO O
N
O
O
 
985.4 
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# Name Structure Mol.wt. [g/mol] 
OJ 480 
F2 
N7-NPE-BG-
Phthal-GLU-
Peg1-Amid-
Peg2-Halo 
 
985.4 
OJ 481 
F1 
N9-NPE-BG-
Phthal-GLU-
Peg2-Amid-
Peg2-Halo 
 
1'029.5 
OJ 481 
F2 
N7-NPE-BG-
Phthal-GLU-
Peg2-Amid-
Peg2-Halo 
 
1'029.5 
OJ 593 
F2 
N7-NPE-BG-
5FPhe-Peg4-
Halo 
 
965.3 
OJ 593 
F1 
N9-NPE-BG-
5FPhe-Peg4-
Halo 
 
965.3 
OJ 594 
F2 
N7-NPE-BG-
CH2-CF3-
Peg4-Halo 
 
867.3 
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# Name Structure Mol.wt. [g/mol] 
OJ 594 
F1 
N9-NPE-BG-
CH2-CF3-
Peg4-Halo 
 
867.3 
OJ 598-
1 F2 
N7-NPE-BG-
HFPO-Peg3-
Halo 
 
1'019.4 
OJ 598-
1 F1 
N9-NPE-BG-
HFPO-Peg3-
Halo 
 
1'019.4 
OJ 587 
F2 
N7-NPE-BG-
(CH2)3-Peg3-
Halo 
 
783.3 
OJ 587 
F1 
N9-NPE-BG-
(CH2)3-Peg3-
Halo 
 
783.3 
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3.3.3.2 Results and Methods 
INTRACELLULAR ONE-SIDED REACTIVITY 
When we first started this project with caged Halo-SNAP dimerizers, we did not have 
recombinant Halo and SNAP proteins and directly measured Halo and SNAP reactivity inside 
living cells. This made it impossible to exclusively address the question of reactivity of the 
newly synthesized molecules without the influence of cell permeability. However, if a 
molecule performed well, we knew that both reactivity and cell permeability were acceptable. 
 
 
Figure 3-16 The molecules’ intracellular reactivity on the Halo side. The reactivity of the compound had to be 
determined indirectly by a second step competition assay. On the right side of the panel, a second step 
incubation with OJ 451 has been performed as well but is not indicated. 
 
As is depicted in Figure 3-16, we measured the intracellular reactivity of caged 
dimerizers at the Halo reactive side with the competition assay. HeLa cells were transfected 
with HaloGFP and 24 hours later the according substance was administered to the cells at a 
concentration of 5 µM in completed medium for 1 hour at 37°C. OJ 451 (Halo TMR) was 
added after a wash step to cells at a concentration of 5 µM in completed medium for an 
additional hour at 37°C. Afterwards, the cells were  lysed with sample buffer and an SDS 
page was performed. In-gel fluorescence was detected with the Typhoon (Image Quant, GE 
healthcare) and the signal was normalized to GFP signal obtained after performing an anti-
GFP western blot. In the competition assay, the values observed during in-gel fluorescence 
originate from the second
 
step added molecule OJ 541. The higher the value the less protein 
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was blocked from the CID in the first step, which reflects a low capacity of reacting with the 
Halo protein inside the cells. 
It became evident that the NPE group improved cell permeability when we compared 
the results of the caged molecules with the results of the uncaged molecules (Figure 3-16). 
This could be clearly seen with the uncaged molecules C 2033, C 2034, OJ 478, and OJ 479 
and their caged analogs C 2008/C 2009, C 2058 N7/C 2058 N9, OJ 480 F2/ OJ 480 F1, and 
OJ 481 F2/OJ 481 F1, respectively (in the case of OJ 481 F2, reactivity was impaired due to 
unknown reasons). Interestingly, N9 caged molecules seemed to be better cell permeable 
than their N7 caged analogs. Judging by this experiment, caging of the Halo SNAP 
dimerizers seemed to be very promising and even helped to improve cell permeability. 
 
 
 
Figure 3-17 Intracellular reactivity of CIDs on the SNAP tag side without uncaging. 
 
To detect if caging the dimerizer on the SNAP side prevents it from reacting, we 
performed a similar experiment as above and tested the SNAP reactivity of the molecules 
inside living cells (Figure 3-17).  
We transfected HeLa cells with SNAP-GFP and 24 hours later the according 
substance was administered to the cells at a concentration of 5 µM in completed medium, 
and incubated for 1 hour at 37°C. TMR-star was added after a wash step to cells at a 
concentration of 5 µM in completed medium and incubated for an additional hour at 37°C. 
Afterwards, the cells were lysed with sample buffer and an SDS page was performed. In-gel 
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fluorescence was detected with the Typhoon (Image Quant, GE healthcare) and the signal 
was normalized to GFP signal obtained after performing an anti-GFP western blot.  
The caging of the molecules showed a clear effect: Reactivity inside living cells was 
impaired (compare the uncaged molecules C 2033 and C 2034 with their caged analogs 
C 2008/C 2009 and C 2058 N7/C 2058 N9, respectively). However, the residual reactivity of 
the caged molecules was as high as 80% in the case of C 2058 N9. Such high background 
reactivity is an objectionable condition for light controlled caged heterodimerization. The 
reason for this high background reactivity remained unclear. Maybe the cage itself does not 
completely prevent the molecule from reacting with the SNAP tag or the caged molecules are 
not stable enough for long time storage and uncaging happened involuntarily. 
 
INTRACELLULAR HETERODIMERIZATION 
Even though we detected high background reactivity we tested the molecules for 
intracellular heterodimerization capacity. As is depicted in Figure 3-18, we co-transfected 
HeLa cells with SNAP-GFP and Halo-GFP and 24 hours later the according substance was 
administered to the cells at a concentration of 5 µM in completed medium, and incubated for 
the indicated time at 37°C. This was followed by tw o washing steps with complete medium 
and a 30 min recovery step at 37°C with complete me dium. Before UV treatment, the cells 
were washed again with complete medium followed by addition of 500 µl of complete 
medium to the cells (3 cm plate). The UV (365nm) treatment was done on ice and lasted 10 
min. Following the procedure, 2 ml of complete medium was added to the plate and let react 
for an additional hour at 37°C. The reaction was st opped by lysis of the cells in sample buffer 
followed by an SDS page and a western blot against GFP. The amount of heterodimers 
formed was quantified with fluorescent second step antibodies on an Odyssey (LI-COR) 
machine. 
The result obtained with this experiment was ambiguous: C 2008 and C 2009 
behaved exactly as expected. Without UV activation, the amount of heterodimers formed 
stayed below 5% (low background reactivity). Upon UV activation, the portion of 
heterodimers formed went as high as 35%. However, UV activation of C 2058 N7 and 
C 2058 N7 was only marginal and the amount of heterodimers formed stayed below 5% 
(Figure 3-18). A valuable explanation for this finding is again the length of the dimerizer (see 
also Figure 3-9). A SNAP caged molecule reacts first with the Halo tag protein. Short CIDs 
such as C 2058 N7 and C 2058 N7 vanish in the deep binding pocket of the Halo tag protein 
and are no longer able to dimerize with the SNAP tag protein. Long molecules such as 
C 2008 and C 2009 were still susceptible for SNAP tag dimerization.  
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Figure 3-18 Heterodimerization inside living cells could be controlled by UV activation. 
 
The repeatable finding of short CIDs vanishing in the Halo tag protein binding pocket 
jeopardized the whole SNAP caged Halo dimerization strategy. It seemed that only long 
CIDs were suitable for this concept. Unfortunately, long dimerizers usually had a bad cell 
permeability (Figure 3-10, PAMPA assay). Figure 3-19 displays further experiments 
investigating intracellular heterodimerization capacity of various CIDs where the same 
discrepancy of long and short CIDs occurred.   
HeLa cells were co-transfected with SNAP-GFP and Halo-GFP and 24 hours later the 
according substance was administered to the cells at a concentration of 5 µM in completed 
medium, and incubated for the indicated time at 37°C. This was followed by two washing 
steps with complete medium and a 30 min recovery step at 37°C with complete medium. 
Before UV treatment, the cells were washed with complete medium, followed by the addition 
of 500 µl of complete medium to the cells (3 cm plate). The UV (365nm) treatment was done 
on ice and lasted 10min. Following the procedure, 2 ml of complete medium was added to 
the plate and let react for an additional hour at 37°C. The reaction was stopped by lysis of 
the cells in sample buffer followed by an SDS page and a western blot against GFP. The 
amount of heterodimers formed was quantified with fluorescent 2nd step antibodies on an 
Odyssey (LI-COR) machine. In the upper panel all samples were UV treated whereas in the 
lower panel untreated samples were compared with UV treated samples. 
98 Results and Methods 
 
Figure 3-19 Heterodimerization capacity inside cells of photo activatable CIDs 
 
In summary, caged heterodimers have a big potential for time and localization 
controlled heterodimerization and there are numerous advantages over non-caged CIDs as 
explained in the introduction of this chapter. However, we encountered several difficulties 
while trying to establish such a system. The biggest problem was the deep binding pocket of 
the Halo tag protein, making subsequent dimerization with the SNAP tag protein highly 
unlikely, especially in the case of short CIDs. There is work ongoing in our lab that addresses 
this problem by introducing a molecular cage at the Halo reactive part of the molecule as an 
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alternative to the rather difficult BG approach. Another problem is that the residual reactivity 
of the caged molecules differs over time. If one compares the results of Figure 3-17 and 
Figure 3-18, a change in background reactivity of both C 2058 N7 and C 2058 N9 can be 
detected (the experiment displayed in Figure 3-18 was done before the experiment displayed 
in Figure 3-17). Hence, caged molecules might decay over time. This issue has to be 
followed-up in the future when working with caged molecules. The only molecules that gave 
satisfying results in terms of inducing heterodimerization upon UV irradiation were the caged 
analogs of our longest molecule C 2033. This structure however showed very bad properties 
in terms of cell permeability. As can be seen in Figure 3-15, we developed additional SNAP-
Halo molecules with a sufficient length for inducing heterodimerization and with an even 
better cell permeability than C 2033 (e.g. OJ 783 and OJ 788). These have not yet been 
caged and it would be definitely interesting to see how these behave in a caged version. 
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3.3.4 Fluorescent SNAP-Halo Molecules 
Fluorescent dimerizers have various advantages over non-fluorescent molecules. 
They can be directly detected in recombinant and cellular assays, their localization inside 
living cells can be visualized with microscopy and even real time detection of heterodimer 
formation are possible using FRET experiments. While we developed the SNAP Halo 
dimerizers described in the previous chapters, we were also trying to establish caged and 
uncaged fluorescent CIDs. However, all the fluorescent molecules tested were poorly cell 
permeable and were thus not usable in an intracellular Halo SNAP heterodimerization 
system.  
3.3.4.1 Fluorescent SNAP-Halo Molecules 
The fluorophores used for the molecules presented in Table 3-7 were either 
tetramethylrhodamine (TMR), diethylaminocoumarin (430), fluorescein (FL), 
dipivaloylfluorescein (DiPFL) or pennsylvania green (PG). Caged N7 and N9 analogs were 
produced at same time to test the molecules for their applicability in UV induced 
heterodimerization. 
 
Table 3-7 A big effort was put into the project of developing fluorescent SNAP halo dimerizers. The molecules 
were always produced in an uncaged and in a N7 and N9 caged version. 
# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] 
C-
2060 
BG-
TMR-
GLU-
PEG2-
Halo 
 
1'054.0 554 580 
C-
2022 
N7-
NPE-
BG-
TMR-
GLU-
PEG2-
Halo  
1'202.1 554 580 
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# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] 
C-
2024 
N9-
NPE-
BG-
TMR-
GLU-
PEG2-
Halo 
 
1'202.1 554 580 
C-
2023 
N7-
NPE-
BG-430-
GLU-
PEG2-
Halo 
 
997.5 421 444/484 
C-
2025 
N9-
NPE-
BG-430-
GLU-
PEG2-
Halo 
 
997.5 421 444/484 
C-
2115 
N9-
NPE-
BG-
UPEG3-
TMR-
PEG2-
Halo  
1'421.4 554 580 
OJ 
458 
N9-
NPE-
BG-FL-
Halo 
 
1'114.5 494 521 
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# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] 
OJ 
457 
BG-FL-
Halo 
 
965.4 494 521 
OJ 
456 
N9-
NPE-
BG-
DiPFL-
Halo 
 
1'282.8 494 521 
OJ 
455 
BG-
DiPFL-
Halo 
 
1'133.6 494 521 
OJ 
504 
BG-
TMR-
GLU-
Peg1-
Amid-
Peg2-
Halo 
 
1'118.6 554 580 
OJ 
502 
N7-
NPE-
BG-
TMR-
GLU-
Peg1-  
1'267.8 554 580 
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# Name Structure Mol.wt. [g/mol] 
Excitation 
[nm] 
Emission 
[nm] 
OJ 
500 
N9-
NPE-
BG-
TMR-
GLU-
Peg1-
Amid-
Peg2-
Halo 
 
1'267.8 554 580 
OJ 
503 
BG-PG-
GLU-
Peg1-
Amid-
Peg2-
Halo 
 
1'070.5 494 514 
OJ 
501 
N7-
NPE-
BG-PG-
GLU-
Peg1-
Amid-
Peg2-
Halo 
 
1'219.6 494 514 
OJ 
499 
N9-
NPE-
BG-PG-
GLU-
Peg1-
Amid-
Peg2-
Halo 
 
1'219.6 494 514 
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3.3.4.2 Results and Methods 
 
ONE-SIDED REACTIVITY 
As already mentioned in chapter 3.3.3, before we decided to generate recombinant 
Halo and SNAP proteins to solely measure the reactivity of the CIDs without being influenced 
by cell permeability, we directly assessed one-sided intracellular reactivity of the molecules.  
 
  
 
Figure 3-20 Intracellular reactivity on the Halo and the SNAP side of the dimerizer is depicted. If the CID was not 
fluorescent, the reactivity of the compound had to be determined indirectly by a competition assay 
 
As Figure 3-20 shows, we transfected HeLa cells with either Halo GFP or SNAP GFP 
and 24 hours later the according substance was administered to the cells at a concentration 
of 5 µM in completed medium for 1 hour at 37°C. Aft erwards, the cells were lysed with 
sample buffer and an SDS page was performed. In-gel fluorescence was detected with the 
Typhoon (Image Quant, GE healthcare) and the signal was normalized to the GFP signal 
obtained after performing an anti-GFP western blot. The quantification values were 
normalized to a tag reactive TMR molecule (OJ 451 for Halo and TMR star for SNAP).  
The CIDs had a very bad reactivity on the SNAP tag side compared to the Halo side 
of the molecule. However, also intracellular one-sided reactivity on the Halo side was very 
low, with a maximum portion of reacted molecules of 50% in the case of C 2024. It is difficult 
SNAP side 
Halo side 
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to compare reactivity at the SNAP and the Halo side in absolute numbers, since they were 
normalized to different standards. These might have different staining capacities for their tag 
proteins themselves. Thus normalization of a CID to a molecule that has itself bad Halo or 
SNAP tag reactivity might result in a high apparent reactivity but still might have a bad 
reactivity in absolute terms. As seen in chapter 3.3.3, caging of the molecule (C 2022 and 
C 2024) seemed to a have a beneficial influence on cell permeability when compared to the 
uncaged analog (C 2060). 
 
 
Figure 3-21 Reactivity on Halo side inside living cells can be detected directly with  fluorescent CIDs 
 
Figure 3-21 shows again the same experiment as displayed in Figure 3-20, with the 
exception that this time the Halo sided reactivity was measured in proportion to the 
fluorescent Halo-reactive molecules OJ 451 and O 489. Since OJ 451 (TMR) and O 489 
(FITC) have different fluorescent properties two different images had to be acquired on the 
Typhoon. The image labeled as "Fluorescence Typhoon" in Figure 3-21 is an overlay of the 
two images. Again, all the molecules tested had a very bad intracellular reactivity probably 
due to their low cell permeability. 
One-sided reactivity was additionally quantified with microscopy. To test intracellular 
reactivity at the Halo side we transfected HeLa cells on glass coverslips with Halo GFP and 
24 hours later the according substance was administered to the cells at a concentration of 
5 µM in completed medium, followed by incubation for one hour at 37°C. The cells were then 
washed with complete medium and UV-treated for 10 minutes at 365 nm. The samples were 
fixed and mounted with Mowiol, and visualized on an Axiovert 200 M microscope (Zeiss). To 
quantify the reactivity of the compound the ratio between the TMR filter picture and the GFP 
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filter picture was calculated. The higher the ratio the better the substance reacted on its Halo 
side inside living cells.  
As already shown in Figure 3-20, the uncaged molecule C 2060 had the lowest cell 
permeability (Figure 3-22). UV treatment of the cells somehow had a negative effect on the 
result, maybe due to bleaching effects of the fluorophore during the UV treatment. 
 
 
Figure 3-22 Intracellular Halo-Tag reactivity of fluorescent CIDs was determined by microscopy 
 
In a further experiment, the same molecules were tested for extracellular reactivity on 
the SNAP-tag side. In contrast to the previous transfection with intracellularly expressed 
Halo GFP we transfected SNAP fused do the transmembrane protein endothelin. Hence, the 
SNAP protein was expressed on the outside of the cell (Figure 3-23). Because the 
endothelin-SNAP construct did not contain GFP or any other fluorescent protein we could not 
normalize the TMR fluorescence directly to expression of the construct. Therefore, we added 
BG 505 (fluorescent in the GFP filter set) at 5 µM in completed medium for 1 hour at 37°C to 
the samples after the incubation of the various CIDs. Again, like in the competition assay, we 
detected indirectly how much of the SNAP proteins had reacted with the CID. To quantify the 
reactivity of the compound using microscopy the ratio between the Rhodamine filter picture 
and the BG505 (GFP) filter picture was calculated. The higher the ratio the better the 
substance reacted extracellularly on its SNAP side. 
Interestingly, a completely different result from the previous experiments (Figure 3-22) 
was observed. The uncaged C 2060, which had the worst intracellular reactivity of the three 
tested substances, performed best when the SNAP-tag was expressed extracellularly. This is 
no surprise since C 2022 and C 2024 are SNAP caged molecules and efficiency of UV 
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activation is never 100%. In fact, UV activation seemed not to be efficient at all because only 
a minor increase of reacted molecules could be observed after UV treatment (Figure 3-23). 
 
Figure 3-23 Extracellular reactivity of CIDs on the SNAP side was determined by microscopy 
 
In Figure 3-24 we quantified the intracellular SNAP-tag reactivity of the same 
compounds already tested in the two experiments before. This time the HeLa cells were 
transiently transfected with SNAP GFP before to the addition of the CIDs to the samples. All 
molecules showed very bad intracellular SNAP-tag reactivity when compared to the negative 
control DMSO. UV activation induced a slight increase in amount of reacted SNAP-tag 
protein when compared to the non UV treated sample. 
 
Figure 3-24 Intracellular SNAP Tag reactivity was very poor as determined by microscopy 
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INTRACELLULAR HETERODIMERIZATION 
Even though one-sided reactivity of the tested fluorescent heterodimerizers was very 
poor we wanted to assess their capacity to dimerize intracellular proteins. We co-transfected 
HeLa cells (Figure 3-25) with SNAP-GFP and Halo-GFP (left panel) or SNAP-GFP and Halo-
GFP-CAAX or Halo-GFP-CAAX and p110gamma-SNAP (right panel). Twenty-four hours 
later the according substance was administered to the cells at a concentration of 5 µM in 
completed medium, and incubated for one hour at 37°C. This was followed by two washing 
steps with complete medium and a 30 min recovery step at 37°C with complete medium. 
Before UV treatment, the cells were washed with complete medium again, followed by the 
addition of 500 µl of complete medium to the cells (3 cm plate). The UV (365nm) treatment 
was done on ice and lasted 10 min. Following the procedure, 2 ml of complete medium was 
added to the plate and the dimerization was left to react for an additional hour at 37°C. The 
reaction was stopped by lysis of the cells in sample buffer followed by an SDS page and a 
western blot against GFP. The heterodimers formed were visualized with conventional ECL. 
Quantification was not possible since the monomeric bands had to be overexposed to 
visualize the heterodimerization bands.  
Even though the amount of heterodimers formed was low, we could show that our 
system has the potential to connect proteins that are in different cellular compartments. We 
were not only able to dimerize cytosolic GFP-tagged proteins, but also cytosolic proteins 
(p110g-SNAP and SNAP-GFP) with membrane bound tags (Halo-GFP-CAAX).  
 
Figure 3-25 Heterodimers were detected in various combinations of dimerization pairs. They were either 
cytosolic (Halo-GFP/SNAP-GFP) or membrane and cytosolic (SNAP-GFP/Halo-GFP-CAAX or p110g-
SNAP/Halo-GFP-CAAX). The amount of dimers formed was low and detected with conventional ECL.  
 
To be able to quantify the amount of heterodimers formed, we developed the western 
blot shown in Figure 3-26 with a fluorescent second step antibody and detected it on an 
Odyssey (LI-COR) machine. The rest of the protocol was performed exactly as described for 
Figure 3-25. C 2034 was used as a positive control since at the time point of the experiment 
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this was the best performing molecule in terms of intracellular heterodimerization capacity. 
Immediately, it could be seen that all the fluorescent molecules formed only minor amounts 
of dimers independently of being caged (OJ 458, OJ 456, C 2023, C 2024) or uncaged 
(OJ 457, OJ 455, C 2034).  
 
Figure 3-26 Heterodimerization capacity inside cells of photo activatable CIDs 
 
An interesting example of the potential of fluorescent SNAP-Halo dimerizers can be 
seen in Figure 3-27. Here we performed again the same experiment as described before 
(Figure 3-25 and Figure 3-26) with the exception that after the SDS page we detected the in-
gel fluorescence using the Typhoon (Image Quant, GE healthcare) machine. Since the 
tested CIDs had different fluorescent properties we had to take two images. One was taken 
with TMR filters and the second one with GFP filters. The resulting pictures were then 
merged. The amount of heterodimers formed was quantified additionally with a western blot 
against GFP and a fluorescent second step antibody that was detected on an Odyssey (LI-
COR) machine. The positive control C 2034 is not fluorescent and can thus not be seen in 
the in-gel fluorescent picture.  
Again, the amounts of heterodimers formed were very low when compared to C 2034 
in the western blot quantification (Figure 3-27). The in-gel fluorescence picture gave insight 
into the distribution of the fluorescent CID inside the cell. We could see that the dimerizer 
preferably located to the Halo-tag or formed dimers. Solely SNAP tag bound dimerizer could 
hardly be found. This finding might again be explained with the deep binding pocket of the 
Halo protein: Molecules reacting first with the SNAP tag could still connect with the Halo tag 
and were thus forming heterodimers. Molecules that reacted first with the Halo tag were no 
longer able to interact with the SNAP tag and no linkage could be formed. The prominent 
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fluorescent Halo band in the in-gel fluorescence picture corroborates this theory (Figure 
3-27). 
 
Figure 3-27 The heterodimerization capacity of caged fluorescent CIDs is limited 
 
In summary, the tested fluorescent Halo-SNAP dimerizers performed badly in one-
sided intracellular reactivity assays and had a low capacity to induce intracellular 
heterodimers. This is most likely due to bad cell permeability. Different kinds of fluorophores 
should be tested to generate molecules that would be cell permeable. 
  
Dimer 
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3.4 Targeting Melanoma with Dual PI3K/mTOR Inhibitors. 
3.4.1 Summary 
 
Phosphoinositide 3-kinases (PI3Ks) play important roles in cell growth, survival and 
motility. Here we investigate the effects of orally-available PI3K inhibitors in melanoma [84, 
85]. Melanoma shows often constitutive activation of the Ras/MAPK and PI3K/PKB/Akt 
pathways, suggesting that those pathways might be key targets in melanoma therapy. 
Treatment of cells with broadband PI3K inhibitors, such as wortmannin or LY294002, 
reduced cell proliferation only negligibly. A new generation of potent PI3K/mTOR inhibitors, 
BAG956, BBD130 and BEZ235, on the other hand, caused complete G1 growth arrest in 
>85% of tested melanoma, reduced the levels of the G1 cyclin cyclin D1 and increased 
amounts of the cell cycle inhibitor p27KIP1. PI3K inhibitor-induced apoptosis was negligible in 
2D cultures, but prominent in cell outgrowth from melanoma spheroids. In a mouse 
melanoma tumor model, orally-applied BBD130 and BEZ235 and intraperitoneal PI103 
efficiently reduced primary tumor growth, while lymph node metastasis was only reduced by 
BBD130 and BEZ235, but not significantly by PI103. The metastasis of BBD130 and 
BEZ235-treated mice contained less mitotic and significantly smaller tumor cells, and 
showed reduced neovascularization and increased necrosis as compared to vehicle control 
mice.  Importantly, the inhibitors were well tolerated in the animals, with no effects on blood 
glucose levels, little liver toxicity or effects on the immune cell repertoire. These results 
suggest that targeting of the PI3K/mTOR pathway in melanoma shows promise with 
acceptable side effects. Clinical trials with BEZ235 entered phase I/II for patients with solid 
tumors. Currently, more experiments are in progress in order to understand the role and the 
importance of the single PI3K class I isoforms in tumor and metastasis formation. 
 
 
My contribution to the following paper "Targeting Melanoma with Dual PI3K/mTOR 
Inhibitors" is summarized in Figure 1, panel D and E. 
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3.4.2 Published Manuscript 
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To study the function of proteins, various approaches have been used over the past 
century. A vast amount of information about genes and their protein function were obtained 
from forward genetic methods. By identifying the mutation that leads to an observed 
phenotype, previously unknown members of signaling pathways and their function can be 
detected. A more recent approach to address the same questions are reverse genetic 
methods. In this case, genes and their protein function are targeted directly with various 
genetic methods. This can be either a complete knockout of the gene, an introduced 
mutation or an induced genetic targeting such as tet/dox or Cre/lox systems [100]. Another 
widely used method to study the function of proteins is the down regulation of the their 
expression with RNA interference methods [101]. All these methods have generated a vast 
amount of valuable information and are still important in everyday research. However, there 
are important limitations of these approaches. Gene knockout studies are not possible when 
the investigated protein is important for development and is thus leading to embryonic 
lethality. On the other hand, it is also common that mutations or knockouts are not resulting 
in any observable phenotype, mostly due to redundant or alternative pathways. This makes it 
nearly impossible to interpret the function of the protein [102].  
Alternative methods to understand protein functions make use of cell-permeable 
small molecules [103]. These methods are very appealing since these chemicals can be 
used in a rapid, dose dependant and even reversible manner. These molecules can inhibit 
the protein of interest by targeting to its active site or they can even prevent interaction with 
other proteins [104-106]. However, these inhibitors often lack specificity and target multiple 
off-target proteins which makes it difficult to interpret the obtained results [54]. Additionally, 
the identification of small molecules that specifically target a protein is very laborious, 
sometimes not possible and certainly not feasible for a proteomic approach. This is the 
reason why methods have been developed that integrate the advantages of the small 
cell-permeable molecules without the need of a unique compound for every protein. As 
described in the introduction of this PhD thesis, chemical induced dimerization has become a 
suitable strategy to potentially regulate and study all proteins. The probability of two 
molecules reactingwith each other declines with distance by an order of two or three [75]. For 
this reason, many biological processes are controlled by the proximity between the 
interacting proteins [107]. Various biological processes have been controlled and studied 
with chemical induced dimerization, such as receptor function, signaling, protein secretion, 
protein stability, transcription, chromosomal separation, apoptosis, protein splicing, and 
protein glycosylation [10, 19, 26, 29, 108-112]. Chemical induced dimerization was even 
successful in gene therapy of murine and primate models, activating genes that were 
therapeutically important [113, 114]. 
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Our group is mainly working on PI3K [81-85] and we are looking for tools allowing us 
to target members of the PI3K pathway specifically to understand their function and to 
identify their interacting partners. Because of all the advantages of chemical dimerizers, we 
planned to adapt them for our purposes. Potential questions we wanted to address with 
chemical dimerization were the role of different regulatory adaptor subunits such as p101 
and p84 in cells expressing both adaptor subtypes [81], the RAS PI3K interaction, or the 
local PIP3 production in polarized cells. We first focused on the best described and most 
used heterodimerization system, the rapamycin system. We knew that the original rapamycin 
system would not be suitable for tampering with proteins included in PI3K signaling. Inhibition 
of TORC1 with rapamycin is not tolerable when investigating upstream proteins of the mTOR 
signaling pathway such as the PI3K. Hence, we thought rapalogs would be the ideal solution 
for our demands. However, when we tested different rapalogs such as iRap [115] or 
AP23102 [8], they inhibited the mTOR downstream protein S6K to a great extent 
(unpublished data). Reasons for this were either contaminations of rapalogs by rapamycin, 
which are extremely difficult to avoid during chemical synthesis of the rapalogs, or undefined 
spatial orientation of the bulky group at the C16 position (see section 2.1.3, rapalogs). Other 
reported CID systems for heterodimerization were as well not very appealing, because they 
either exert effects on endogenous proteins (MTX [65, 71], DEX [65], Estrone [58, 59]) or 
were more complicated due to their three components design (biotin system [55]). 
This was the starting point for this PhD project and our goal was to develop a novel 
chemically induced heterodimerizing system that would not interfere with endogenous 
signaling cascades. Additionally, for better applicability, the CID should have a fast 
intracellular reactivity and have a high selectivity towards the protein tags. Moreover, the 
system should be able to be introduced into living cells and organisms and therefore the CID 
must be non-toxic, and highly cell permeable. Another important point would be that the 
linkage between the protein tags induced by the CID is stable and is not degraded over time. 
Last but not least, the chemical synthesis of the CID should be feasible with high yield. We 
tried different approaches to reach this goal and not all strategies proved to be successful.  
However, with one approach we successfully introduced a novel chemically induced 
heterodimerization system that combined most of desired properties for such a method. For 
the strategy we focused on the development of a SNAP-Halo heterodimerization system. 
Even though these reactive protein tags have been described previously, they have never 
been combined in one heterodimerization system. Both tags form covalent bonds with its 
specific substrates, thus forming an extremely stable linkage. The Halo tag has high 
specificity and reactivity towards carbon-halogen bonds in aliphatic compounds and there is 
no endogenous counterpart in eukaryotic organisms known so far. The SNAP tag is modified 
in a way that the BG substrate is almost 60 times more active towards the SNAP tag than 
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endogenous hAGT [70]. Linking the two reactive modules (BG for SNAP and chloro-alkane 
for Halo) in one molecule yields a molecule that has the capacity to bring together the two 
reactive protein tags. 
Developing a small (≤ 800 Dalton) bivalent cell permeable organic molecule that 
incorporates the SNAP and the Halo reactive moiety was a laborious task. The one-sided 
reactivity of the dimerizer to the tag proteins was achieved already at the beginning of the 
project, as could be shown with recombinant SNAP and Halo proteins. The real task was the 
development of cell permeable dimerizers. Because the SNAP- and Halo tag substrate had 
been optimized previously [74, 80, 116], we focused only on the linker region between the 
reactive moieties (chapter 3.3.1) of the dimerizer to improve cell permeability. The chemical 
optimization of the spacer included integration and substitution of groups modulating water 
solubility, cell permeability and bulky or semi-rigid structures separating the two tag-reactive 
moieties. Inspired by pharmacochemistry, we found out that fluorinated, small hydrophobic 
linkers were optimal in terms of cell permeability. This was illustrated with PAMPA assay and 
one-sided intracellular reactivity. However, for optimal intracellular heterodimerization 
capacity, the linker required a minimal length to connect the reactive tags. A model 
connecting the SNAP and Halo tag with our best dimerization molecule OJ767 revealed that 
shorter dimerizers are energetically not favorable or are sterically not capable to connect the 
two tag proteins. The fact that small molecules are better cell permeable is opposing the 
finding that a certain minimal length is required to efficiently dimerize the proteins. Hence, 
optimal linker length had to be determined empirically. Quantification of the 
heterodimerization capacity of various newly synthesized Halo-SNAP dimerizers was 
straightforward due to the dual covalent reactivity with the protein tags. Compared to other 
CID systems such as the rapamycin method, formed intracellular heterodimerization is stable 
even in denaturing SDS gels and western blots and can thus be quantified easily. This 
allowed the fast and direct comparison between different dimerizers not depending on 
indirect read-outs such as gene expression assays in yeast [55]. The direct correlation 
between compound structure and intracellular reaction kinetics allowed us to improve 
sequentially the properties of our compounds. In short, we first determined the optimal length 
of the dimerizer, then found out that hydrophobic side chains help to improve cell 
permeability and that this could even be increased by fluorination of the side chain. By 
incorporation of the hydrophobic fluorinated side group into the backbone of the dimerizer we 
obtained our final and best compound OJ767. With this incorporation we kept all the 
favorable properties but decreased its molecular weight, which, as mentioned earlier, is very 
important for cell permeability. OJ767, our fast intracellular heterodimerizer, was successfully 
used in various cellular assays. For the first time, we were able to target different cellular 
structures. Upon induction by OJ767, cytosolic Halo tag was either translocatedto 
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membrane- or actin-anchored SNAP tag. This proved that our dimerizer is not only inducing 
interaction between cytosolic proteins but also between proteins from different cellular 
compartments. We could also show that our system has the potential to tamper with 
signaling pathways. Translocation of the iSH2 domain of p85 [117] to the cell membrane led 
to a subsequent activation of downstream PI3K targets, such as PKB and S6K. In contrast to 
a ligand induced receptor tyrosine kinase (RTK) activation where multiple pathways (such as 
the PI3K and the MAPK pathway) get activated, we were able to specifically induce a single 
pathway.  
The capacity to tamper with signaling pathways makes our newly developed 
heterodimerization system an ideal research tool and a more than valuable alternative to 
existing heterodimerization systems. Our dimerizer can be used at nanomolar concentrations 
and has no effect on endogenous mTOR, in opposition to rapamycin/rapalog system. For the 
first time, a dual covalent dimerizer has been introduced. This highly stable protein 
dimerization has several advantages over non covalent systems. It allows the quantification 
of formed dimers in SDS gels and western blots correlating heterodimers to output signals 
such as protein phosphorylation or gene transcription. Because reacted dimerizers cannot be 
washed out, pulse-chase experiments are possible as well. For example, a dimerizer induced 
signaling cascade stays active even after extensive washout since the covalently linked 
protein dimers are not affected. Feedback mechanisms potentially down-regulate the 
dimerizer induced signaling cascade after the activation. This makes it interesting to observe 
if the dimerization of newly synthesized signaling proteins will lead to reactivation of the 
signaling cascade. Our system can possibly even be used in high-throughput interaction 
studies. For the Halo tag, over 7000 validated human fusion proteins can already be 
purchased. Linking them to SNAP fusion proteins can identify novel protein interactions. 
Our system works nicely in cell culture. The next step would be its validation for in 
vivo use with a genetically modified mouse that expresses the SNAP and Halo tag fused to 
appropriate reporter genes. If our dimerizer is suitable for whole organisms our system could 
even be used in gene therapy, activating therapeutically important genes.  
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6.1 Halo Molecules 
The following Halo-tag reactive molecules were also produced an tested during the 
SNAP-Halo project but were not addressed in detail in the body of this Ph.D. thesis 
Product# C-1989 
Name HCl  NH2-Halo 
Mol. wt. [g/mol] 223.74 
Formula C10H22ClNO2 
Structure 
 
Product# OJ 451 
Name Halotag TMR 
Mol. wt. [g/mol] 672.638 
Formula C35H43Cl2N3O6 
Structure 
 
Product# OJ 489 
Name Halotag PG 
Mol. wt. [g/mol] 588.039 
Formula C31H32ClF2NO6 
Structure 
 
Product# OJ-622 
Name TMR-6NH-Halo 
Mol. wt. [g/mol] 804.374 
Formula C42H54ClN7O7 
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Structure 
 
Product# OJ-634 
Name TMR-6N(NPE)-Halo 
Mol. wt. [g/mol] 953.521 
Formula C50H61ClN8O9 
Structure 
 
Product# OJ-623 
Name TMR-3NH-Halo 
Mol. wt. [g/mol] 762.294 
Formula C39H48ClN7O7 
Structure 
 
Product# OJ-633-1 
Name TMR-3N(NPE)-Halo 
Mol. wt. [g/mol] 911.441 
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Formula C47H55ClN8O9 
Structure 
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6.2 Plasmids 
The following plasmids were generated 
during the thesis. The plasmids used for the 
manuscript (chapter 3.3.1) are indicated in the 
remarks. 
  
# Backbone Insert / Name Remarks
1408 pcDNA3 Lyn -- Halo
1409 pcDNA3 Halo Tag 7-eGFP-CAAX
1410 p(noGFP) Halo Actin
1411 pcDNA3 Halo - CAAX
1413 SNAP (pSS26m) From Covalys
1414 pGEX-2T NAGT From Kai Johnsson
1415 SNAP-ADB2 From Covalys
1416 SNAP-Endothelin From Covalys
1417 pcDNA3 SNAP-EGFP Used in Halo-SNAP publication
1418 pcDNA3 SNAP-EGFP-CAAX Used in Halo-SNAP publication
1419 pcDNA3 SNAP-EGFP-DeltaCAAX
1420 pcDNA3 SNAP-EGFP-RIT
1421 pcDNA3 SNAP-EGFP-DeltaRIT
1422 pcDNA3 nAGT-eGFP
1423 pTagRFP SNAP26
1424 pcDNA3 SNAP-p110g     
1425 pcDNA3 SNAP-p110g-DeltaCAAX
1426 pcDNA3 SNAP-p110g-RIT
1427 pcDNA3 SNAP-p110g-DeltaRIT
1428 pcDNA3 SNAP26 p110alpha
1429 pcDNA3 p110g-SNAP
1430 pcDNA3 SNAP-p101
1431 pcDNA3 PH (BTK)-SNAP
1432 pcDNA3 FYVE-SNAP
1433 pcDNA3 PH (PLCd)-SNAP
1434 pEGFP-C1 SNAP
1435 pEGFP-C1 SNAP-SNAP
1436 pEGFP-C1 SNAP-SNAP-SNAP
1437 pEGFP-N3 CLIP
1438 pTagRFP-N CLIP
1439 pCEMS1 CLIPm from covalys
1440 pcDNA3 2xFKBP12-eGFP-CAAX
1441 pTagRFP-N FRB
1442 pTagRFP-N FRB (T2098L)
1443 p(noGFP)N3 p110g-FRB
1444 pTagRFP-N Halo Used in Halo-SNAP publication
1445 pEGFP-N3 Halo Used in Halo-SNAP publication
1446 pTriEx4 EGFP SNAP Used in Halo-SNAP publication
1447 pTriEx4 EGFP Halo Used in Halo-SNAP publication
1448 mRFP-FKBP-Hras G12V From Karsten Schulz
1449 mRFP-FKBP-Hras S17N From Karsten Schulz
1450 Lck-FRB T2098L-ECFP From Karsten Schulz
1451 pcDNA3 SNAP -- CAAX
1452 pcDNA3 Lyn -- SNAP
1453 pcDNA3 LynHalo
1454 pcDNA3 LynSNAP
1455 pcDNA3 SNAP -- -- HRasG12V
1456 pcDNA3 Halo HRasG12V
1457 pcDNA3 SNAP HRasG12V
1458 pcDNA3 Halo HRasS17N
1459 pcDNA3 SNAP HRasS17N
1460 pEGFP Actin Clonetech (ob. from O. Pertz)
1461 p(noGFP) Snap Actin Used in Halo-SNAP publication
1462 pcDNA3 CD8 Halo
1463 pcDNA3 CD8 SNAP
1464 pcDNA3 FceRg Halo
1465 pcDNA3 FceRg SNAP
1476 pcDNA3 Halo - p85iSH2
1477 pcDNA3 SNAP - p85iSH2
1478 pEGFP-N3 FRB
1479 pEGFP-C3 Halo iSH2 Used in Halo-SNAP publication
1480 pEGFP-C3 Snap iSH2
1481 pSG9M myc Halo iSH2
1482 pSG9M myc SNAP iSH2
1483 pSYFP Halo iSH2
1484 pTurquoise Halo iSH2
1485 pcDNA3 SNAP pSYFP CAAX
1486 pcDNA3 SNAP pTurquoise CAAX
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